

## CONTENT

### 3.5.1

The number of MoUs, collaborations/linkages for Faculty exchange, Student exchange, Internship, Field trip, On-the-job training, research and other academic activities during the last five years

**INDEX**

S.No.	MOU	Page No.
1	<a href="#"><u>Aditya Birla Memorial Hospital ,Pune</u></a>	3-16
2	<a href="#"><u>Gansons, Mumbai</u></a>	17-28
3	<a href="#"><u>Sciformix, Pune</u></a>	29-39
4	<a href="#"><u>Electrolab Mumbai</u></a>	40-50
5	<a href="#"><u>Abbott Healthcare Pvt Ltd, Mumbai</u></a>	51-55
6	<a href="#"><u>McW, Indore</u></a>	56-65
7	<a href="#"><u>Mprex, Pune</u></a>	66-82
8	<a href="#"><u>Jehangir Centre for Learning, Pune</u></a>	83-104
9	<a href="#"><u>V-Ensure Pharma Technologies Pvt Ltd, Mumbai</u></a>	105-120
10	<a href="#"><u>Pharmaelite, Mumbai</u></a>	121-133
11	<a href="#"><u>Manipal Institute of Virology, Manipal</u></a>	134-140

MOU

Aditya Birla Memorial Hospital



महाराष्ट्र MAHARASHTRA      2015      V 119304

अनु क्र. 92210 31 AUG 2015      मु.मु.रकम 500/-

दस्तावेज प्रकार ..... मु.मु.रकम 500/-

दस्त नोटमी कागजर आहेत का ? होय/नाही.

पिठ हातीचे दर्शन .....

मुद्रांक विभाग ..... इंदिरा कॉलेज ऑफ फार्मसी

पत्ता ..... ता. मुंबई जि. पुणे

इसके समकालीन मुद्रांक ..... आदित्य बिरला होस्पिटल

हस्त लेखक ..... लीलाजी यशमकर काठार

श्री. शोभा ज. डोबे  
संपन्न क्र. 2209944

मुद्रांक विभाग कोसपानी वॉ. कोसपुणे, सैन रोड, काठारजी, पुणे-१७

28 AUG 2015

जो कारणासाठी ज्यांनी मुद्रांक घेरेदी केला त्यांनी त्याच कारणासाठी मुद्रांक घेरेदी केला पावुन 6 महिन्यात वापरणे कोसपुणे आहे

**MEMORANDUM OF UNDERSTANDING**

This memorandum of under taking is made on 31<sup>st</sup> August 2015, between Aditya Birla Memorial Hospital, Chinchwad, Pune which is represented by its Chief Executive Officer herein named as party one and SCES's, Indira College of Pharmacy, Tathwade Pune, affiliated to Savitribai Phule Pune University, Pune, represented by Principal herein named as party two. The parties hitherto agree as follows:

1. Party one declares that the **Aditya Birla Memorial Hospital, Chinchwad**, is **500 bedded hospitals**, with minimum of 52 beds for General Medicine Department.
2. Party one agrees to provide party two the minimum space necessary of 1200 square feet in the hospital building to establish Pharmacy Practice Department for the conduct of Pharm. D Programme.
3. Party one provides to agree preceptors required to train the Pharm. D. students.
4. Party one agrees that it will not enter into similar agreement with any other pharmacy institution/s or department/s offering or intend to offer Pharm D programme.
5. The prospective students will be allowed to undergo training in the following specialty departments:
  - Medicine
  - Surgery
  - Pediatrics
  - Gynecology and Obstetrics
  - Orthopedics
6. Party two will provide academic staff and necessary infrastructure for Pharm D. course as per the PCI norms and takes the overall responsibility for smooth conduct of the programme.
7. This agreement is to be in effect at least for the **ten years** from the time of its endorsement by both the parties.
8. The officials representing **Aditya Birla Memorial Hospital, Chinchwad** and **SCES's Indira College of Pharmacy, Pune** are signing this MOU to achieve the beneficial objectives of Pharm. D. programme.



*Rekha Dubey*  
**Rekha Dubey**  
 Hospital Authority  
 Chief Executive Officer  
 Aditya Birla Memorial Hospital  
 Chinchwad, Pune 411033

*Anagha Joshi*  
**Dr. Anagha Joshi**  
 Principal  
 Indira College of Pharmacy  
 Tathwade,  
 Pune- 411033.

*Tarita Shankar*  
**Dr. Tarita Shankar**  
 Witness  
 Founder Secretary  
 & Chief Managing Trustee  
 Shree Chanakya Education Society  
 Tathwade, Pune 411033



**BEFORE ME**  
*M. V. Kirad*  
**M. V. KIRAD**  
 NOTARY GOVT. OF INDIA.  
 PUNE.

**31 AUG 2015**

## SUMMARY



Shree Chanakya Education Society's  
**Indira College of Pharmacy, Pune**  
 "Redefining Pharmacy Education"


**NAAC: B++**

Approved by PCI, AICTE, New Delhi, Affiliated to SPPU & MSBTE, Recognized by Govt. of Maharashtra

### SUMMARY

Title: Activities carried out under MOU (Aditya Birla Hospital)				
S.No.	Name of the Activity	Year	Topic	Class
1	Research Projects	2020-2021	Prescription Adherence to Secondary Prevention Guidelines And Relationship Between Patient Non-Adherence And Morbidity in Acute Coronary Syndrome (ACS) and Chronic Coronary Syndrome (CCS) Patients	Fifth Year Pharm D
2	Research Projects	2020-2021	Medication Management of COVID-19 Patients without Co-Morbidities"	Fifth Year Pharm D
3	Research Projects	2020-2021	Prescription analysis and monitoring of adverse drug reactions of anti-cancer agents in tertiary care hospital.	Fifth Year Pharm D
4	Research Projects	2020-2021	Adherence of Antibiotic Prescription to WHO Indicators and Clinical Response Rate in Critically Ill Patients Treated with Meropenem in a Tertiary Care Hospital	Fifth Year Pharm D
5	Research Projects	2020-2021	Study on blood pressure control in patients on long term hemodialysis and effects on quality of life	Fifth Year Pharm D
6	Research Projects	2020-2021	Comparison of Different Drug Regimens Used In Post- Surgical Pain Management In a Tertiary Care Hospital	Fifth Year Pharm D
7	Research Projects	2020-2021	Prescription adherence to ags beer's criteria in geriatric patients in a tertiary care hospital"	Fifth Year Pharm D
8	Research Projects	2020-2021	Prescription audit to identify adverse drug reactions (ADRs) and report them in the Pharmacovigilance Centre of the hospital	Fifth Year Pharm D
9	Research Projects	2020-2021	To Study the Effect of Drug Therapy in COVID-19 patients with Comorbidities	Fifth Year Pharm D
10	Research Projects	2020-2021	Assessment of Effectiveness of Antihypertensives In Blood Pressure Control and its Complaints with Joint National Committee 8 (JNC 8) guidelines in a tertiary care hospital	Fifth Year Pharm D



  
 Dr. Anagha M Joshi  
**PRINCIPAL**  
 Indira College of Pharmacy  
 Tathawade, Pune - 411 033



Shree Chanakya Education Society's  
**Indira College of Pharmacy, Pune**

*"Redefining Pharmacy Education"*

**NAAC: B++**

Approved by PCI, AICTE, New Delhi, Affiliated to SPPU & MSBTE, Recognized by Govt. of Maharashtra

Title: Activities carried out under MOU (Aditya Birla Hospital)				
S.No.	Name of the Activity	Year	Topic	Class
11	Research Projects	2021-2022	A study of complications in patients undergoing Maintenance Haemodialysis: An Experience in a Tertiary Care Hospital	Fifth Year Pharm D
12	Research Projects	2021-2022	Comparison of the clinical usage pattern of dual antiplatelet therapy (DAPT) and their major and minor bleeding incidences in the Indian population	Fifth Year Pharm D
13	Research Projects	2021-2022	Assessment of nutritional status, use of nutritional supplements and their adherence during pregnancy	Fifth Year Pharm D
14	Research Projects	2021-2022	Drug utilization review in heart failure with reduced ejection fraction (HFrEF) in a tertiary care hospital	Fifth Year Pharm D
15	Research Projects	2021-2022	Study of Topical Steroid Use in Patients Visiting Dermatology Outpatient Department in a Tertiary Care Hospital	Fifth Year Pharm D
16	Research Projects	2021-2022	Study on treatment of anaemia of haemodialysis patients in a tertiary care hospital	Fifth Year Pharm D
17	Research Projects	2021-2022	Drug utilization of novel oral anticoagulants in various thrombotic states in a tertiary care hospital	Fifth Year Pharm D
18	Research Projects	2021-2022	Study of effectiveness of antihypertensives in diabetes patients and its impact on blood pressure and glucose level in tertiary care hospital	Fifth Year Pharm D
19	Research Projects	2021-2022	Assessment of Incidence of Infection in Cancer Patients on Chemotherapy in a Tertiary Care Hospital	Fifth Year Pharm D
20	Research Projects	2021-2022	To study the prescription pattern of antibiotics and its compliance with Standard Treatment Guidelines (STG) for antimicrobial use in infections	Fifth Year Pharm D
21	Internship	2021-2022	Clinical Pharmacy	Final Year B. Pharm



Dr. Anagha M Joshi

**PRINCIPAL**  
(Principal)  
Indira College of Pharmacy  
Tathawade, Pune - 411 033



*Shree Chanakya Education Society's*  
**Indira College of Pharmacy, Pune**

*"Redefining Pharmacy Education"*

**NAAC: B++**

Approved by PCI, AICTE, New Delhi, Affiliated to SPPU & MSBTE, Recognized by Govt. of Maharashtra

Title: Activities carried out under MOU (Aditya Birla Hospital)				
S.No.	Name of the Activity	Year	Name of the Students	Class
22	Internship	2021-2022	Ahmed Summaiyya Shahzad	Sixth Year Pharm D
23	Internship	2021-2022	Bhade Nupur Shashank	Sixth Year Pharm D
24	Internship	2021-2022	Bramhe Prerna Dhanlal	Sixth Year Pharm D
25	Internship	2021-2022	Choudhary Suman Hansaram	Sixth Year Pharm D
26	Internship	2021-2022	Damania Himani Kalpesh	Sixth Year Pharm D
27	Internship	2021-2022	Deshmukh Arohi Jeevan	Sixth Year Pharm D
28	Internship	2021-2022	Deshmukh Dhanraj Pralhadrao	Sixth Year Pharm D
29	Internship	2021-2022	Deshmukh Pourmima Senapati	Sixth Year Pharm D
30	Internship	2021-2022	Deshmukh Ranjeet Ramesh Rao	Sixth Year Pharm D
31	Internship	2021-2022	Deshpande Shruti Raghvendra	Sixth Year Pharm D
32	Internship	2021-2022	Dhakne Rucha Pralhad	Sixth Year Pharm D
33	Internship	2021-2022	Gosar Dhruvi Atul	Sixth Year Pharm D
34	Internship	2021-2022	Gundale Sayali Nitin	Sixth Year Pharm D
35	Internship	2021-2022	Kadam Shubhangi Sanjay	Sixth Year Pharm D
36	Internship	2021-2022	Kale Kimaya Suryakant	Sixth Year Pharm D
37	Internship	2021-2022	Kandalkar Saloni Vijayrao	Sixth Year Pharm D
38	Internship	2021-2022	Khirade Akshay Jagannath	Sixth Year Pharm D
39	Internship	2021-2022	Kolhe Damini Yogesh	Sixth Year Pharm D
40	Internship	2021-2022	Luniya Sharul Sajjankumar	Sixth Year Pharm D

*Anagha M Joshi*  
**Dr. Anagha M Joshi**  
**(Principal)**

**INDIRA**  
**Indira College of Pharmacy**  
**Tathawade, Pune - 411 033**







*Shree Chanakya Education Society's*  
**Indira College of Pharmacy, Pune**

*"Redefining Pharmacy Education"*

**NAAC: B++**

Approved by PCI, AICTE, New Delhi, Affiliated to SPPU & MSBTE, Recognized by Govt. of Maharashtra

Title: Activities carried out under MOU (Aditya Birla Hospital)				
S.No.	Name of the Activity	Year	Name of the Students	Class
41	Internship	2021-2022	Pandey Yogesh Mahavir	Sixth Year Pharm D
42	Internship	2021-2022	Patwardhan Samruddhi Nitin	Sixth Year Pharm D
43	Internship	2021-2022	Pavitra Mahesh	Sixth Year Pharm D
44	Internship	2021-2022	Peerkhan Aiman Mohammad Hanif	Sixth Year Pharm D
45	Internship	2021-2022	Raut Shrikant Baburao	Sixth Year Pharm D
46	Internship	2021-2022	Rede Shital Mahadev	Sixth Year Pharm D
47	Internship	2021-2022	Shaikh Nikhat Altaf	Sixth Year Pharm D
48	Internship	2021-2022	Shimpi Jasmin Yuvraj	Sixth Year Pharm D
49	Internship	2021-2022	Survase Vaishnavi Malhari	Sixth Year Pharm D
50	Internship	2021-2022	Thuthinal Arya Sobhanakumar	Sixth Year Pharm D
51	Internship	2021-2022	Tripathi Shubham Sanjeev	Sixth Year Pharm D
52	Internship	2021-2022	Anju Sam	Sixth Year Pharm D
53	Internship	2021-2022	Gandhi Saurabh Santosh	Sixth Year Pharm D
54	Internship	2021-2022	Jamdade Sonali Ankush	Sixth Year Pharm D
55	Internship	2021-2022	Kamble Manasi Ramchandra	Sixth Year Pharm D
56	Internship	2021-2022	Lamage Sujata Tukaram	Sixth Year Pharm D
57	Internship	2021-2022	Parage Nikita Ashok	Sixth Year Pharm D
58	Internship	2021-2022	Patil Jui Deepak	Sixth Year Pharm D
59	Internship	2021-2022	Rajput Jyoti Gurmej	Sixth Year Pharm D
60	Internship	2021-2022	Sasawade Tanvi Sanjay	Sixth Year Pharm D
61	Internship	2021-2022	Hani Hani Aws	Sixth Year Pharm D



*Anagha M Joshi*  
**PRINCIPAL**  
**Indira College of Pharmacy**  
**Tathawade, Pune - 411 033**



Research Projects

Criterion - III – Research, Innovations & Extension

SSR

2022

Research Projects

Dr. Rajesh Badani  
MBBS, MD, DNB (Med), FCPS, DNB (Cardiology), FESC, FSCAI (USA)  
Sr. Consultant Interventional Cardiology  
Aditya Birla Memorial Hospital,  
Chinchwad- 411033.

CERTIFICATE

This is to certify that the work presented in the dissertation entitled "*Prescription Adherence to Secondary Prevention Guidelines and Relationship between Patient Non-Adherence and Morbidity in Acute Coronary Syndrome (ACS) and Chronic Coronary Syndrome (CCS) Patients*" for the degree of Pharm. D, in the faculty of Pharmaceutical Sciences has been carried out by Ms. Arya Thuthinal, Ms. Nupur Bhade, Mr. Akshay Khirade and Ms. Nikita Parage at SCES's Indira College of Pharmacy, Pune-411033, under my guidance and to my satisfaction. This report is now ready for examination. Materials and services obtained from various sources have been duly acknowledged in the thesis.

(Dr. Rajesh Badani)  
Preceptor

Dr. Rajesh S. Badani  
MBBS, MD, DNB (Med), FCPS, DNB (Cardiology), FESC, FSCAI (USA)  
Sr. Consultant Interventional Cardiology  
Aditya Birla Memorial Hospital,  
Chinchwad- 411033.

Date:

Place: Pune



PRINCIPAL  
Indira College of Pharmacy  
Tathawade, Pune - 411 033

SCES'S Indira College of Pharmacy, Pune

## Research Projects

Criterion - III – Research, Innovations &amp; Extension

SSR

2022




## Research Projects

Dr. Prashant Gaikwad  
MBBS,MD (Internal Medicine),  
Associate Consultant Internal,  
Aditya Birla Memorial Hospital,  
Chinchwad Pune- 411033.

## CERTIFICATE


This is to certify that the work presented in the dissertation entitled "*Prescription adherence to American Geriatric Society (AGS) Beer's Criteria in geriatric patient in a tertiary care hospital*" for the degree of Pharm. D, in the faculty of Pharmaceutical Sciences has been carried out by Ms. Summaiyya Ahmed, Ms Pavitra Mahesh, Ms. Rucha Pralhad Dhakne, Ms. Sonali Ankush Jamdade at SCES's Indira College of Pharmacy, Pune-411033, under my guidance and to my satisfaction. This report is now ready for examination. Materials and services obtained from various sources have been duly acknowledged in the thesis.

  
(Dr. Prashant Gaikwad)  
Preceptor

Date: 26/08/21

Place: Pune



  
PRINCIPAL  
Indira College of Pharmacy  
Tathawade, Pune - 411 033

SCES'S Indira College of Pharmacy, Pune

**Research Projects**

Criterion - III – Research, Innovations & Extension

SSR

2022



**Research Projects**

Dr. Sati Nath Mohanty  
(MD, PDCC, FICA, FIPM)  
Director Anaesthesiology and Director Academics  
Aditya Birla Memorial Hospital,  
Chinchwad- 411033.

**CERTIFICATE**

This is to certify that the work presented in the dissertation entitled "Comparison of Different Drug Regimens Used In Post- Surgical Pain Management In a Tertiary Care Hospital" for the degree of Pharm. D, in the faculty of Pharmaceutical Sciences has been carried out by Ms. Aiman Peerkhan, Ms. Samruddhi Patwardhan, Mr. Saurabh Gandhi, Mr. Yogesh Pandey at SCES's Indira College of Pharmacy, Pune- 411033, under my guidance and to my satisfaction. This report is now ready for examination. Materials and services obtained from various sources have been duly acknowledged in the thesis.



(Dr. S N Mohanty)

**DR. SATI NATH MOHANTY**  
MBBS, MD (ANAESTHESIA), PDCC, FICA, FIPM  
DIRECTOR ANAESTHESIOLOGY &  
ACADEMICS  
REG. NO. : 2019030891  
ADITYA BIRLA HEALTH SERVICES PVT. LTD.  
CHINCHWAD, PUNE-411 033.




**PRINCIPAL**

**Indira College of Pharmacy  
Tathawade, Pune - 411 033**

Date:

Place: Pune



*SCES'S Indira College of Pharmacy, Pune*

**Research Projects**

Criterion - III – Research, Innovations &amp; Extension

SSR


2022

**Research Projects**

Dr. Ravi Wategaonkar  
Medical Oncologist  
M.D.(Medicine), D.M.(Medical Oncology)  
Aditya Birla Memorial Hospital,  
Chinchwad- 411033.

**CERTIFICATE**

This is to certify that the work presented in the dissertation entitled "Assessment of incidence of Infection in Cancer patients on chemotherapy in a Tertiary Care Hospital." for the degree of Pharm. D, in the faculty of Pharmaceutical Sciences has been carried out by Mr. Bhupendra Lakhan Singh, Mr. Hrishikesh Sudesh Khedkar, Mr. Suyash Suryabhan Patil, Mr. Tushar Jagannath Shendge at SCES's Indira College of Pharmacy, Pune-411033, under the my guidance and to my satisfaction. This report is now ready for examination. Materials and services obtained from various sources have been duly acknowledged in the thesis.

  
PRINCIPAL**Indira College of Pharmacy  
Tathawade, Pune - 411 033**  
(Dr. Ravi Wategaonkar)  
Preceptor

Date: 2.3/05/2022

Place: Pune



Dr. Ravikumar N. Wategaonkar  
M. D. Medicine, D. M. Oncology  
Medical Oncologist & Haematologist  
Reg. No 2008/10/3208

**SCES'S Indira College of Pharmacy, Pune**

Research Projects

Criterion - III – Research, Innovations & Extension

SSR

2022




Research Projects

Dr. Sunil Khet  
MBBS, DNB (PEDIATRICS), DNB (NEPHROLOGY)  
Aditya Birla Memorial Hospital,  
Chinchwad-411033.


CERTIFICATE

This is to certify that the work presented in the dissertation entitled "A study of complications in patients undergoing maintenance hemodialysis: An experience in a tertiary care hospital." for the degree of Pharm. D, in the faculty of Pharmaceutical Sciences has been carried out by Ms. Anamika Bhoyar, Mr. Dhiraj Kukreja, Ms. Rutuja Kumbhar, Mr. Rameshwar Rathod at SCES's Indira College of Pharmacy, Pune-411033, under my guidance and to my satisfaction. This report is now ready for examination. Materials and services obtained from various sources have been duly acknowledged in the thesis.

  
(Dr. Sunil Khet)  
Preceptor

Date:

Place: Pune

  
**PRINCIPAL**  
Indira College of Pharmacy  
Tathawade, Pune - 411 033



SCES'S Indira College of Pharmacy, Pune



Internship

Criterion - III

SSR

2022



Internship

**ADITYA BIRLA MEMORIAL HOSPITAL**

Ref. No. : ABMH/HR/Internship/ 5605

08/11/2021

**TO WHOMSOEVER IT MAY CONCERN**

This is to certify that Ms. Rachna Mundhe has completed her 2 months Internship at Aditya Birla Memorial Hospital, Pune in Clinical Pharmacy Dept. from 25<sup>th</sup> Aug. 2021 to 30<sup>th</sup> Oct. 2021.

We wish her "All the Best" in her future endeavor.

for Aditya Birla Health Services Limited,

*[Signature]*  
 Mr. Manoj Prabhu  
 Sr. General Manager – Pharmacy

*[Signature]*  
 Ramesh Kumar Dixit  
 Deputy General Manager – HR

**ADITYA BIRLA HEALTH SERVICES PRIVATE LIMITED**  
**MAHARASHTRA'S FIRST JCI AND NABH ACCREDITED HOSPITAL**  
 Aditya Birla Memorial Hospital, P.O., Chinchwad, Pune - 412 012, Tel. : 020-2612 5071/500 to 04  
 Fax No. : 020-2612 5071/500 For Emergency Call +91-20-2612 1212  
 CHLMS199H2061FC1948, Email: mail@adityabirla.com, web: www.adityabirlahospital.com



*[Signature]*  
**PRINCIPAL**  
 Indira College of Pharmacy  
 Tathawade, Pune - 411 033

SCES'S Indira College of Pharmacy, Pune


Internship



CERTIFICATE OF INTERNSHIP


This is to certify that Sixth Year Pharm D Students of Shree Chanakya Education Society's Indira College of Pharmacy, Pune have successfully completed Internship at Aditya Birla Memorial Hospital, Chinchwad, Pune-411033 as per attached document.

Date: 12/7/2022



(Dr. Sati Nath Mohanty)  
Director Academics

Aditya Birla Memorial Hospital  
Chinchwad, Pune-411033, FIPH  
DIRECTOR ANAESTHESIOLOGY &  
ACADEMICS  
REG. NO. : 2019030091  
ADITYA BIRLA HEALTH SERVICES PVT. LTD.  
CHINCHWAD, PUNE-411 033.



PRINCIPAL  
Indira College of Pharmacy  
Tathawade, Pune - 411033.



ADITYA BIRLA HEALTH SERVICES PRIVATE LIMITED  
MAHARASHTRA'S FIRST JCI AND NABH ACCREDITED HOSPITAL

Aditya Birla Hospital Marg, P.O. Chinchwad, Pune - 411 033, Tel. : +91-20-30717500 to 04  
Fax No. +91-20-30717755 For Emergency Call +91-20-30717777  
CIN:U85199PN2001PTC019881, Email: healthcare@adityabirla.com, Web: www.adityabirlahospital.com





[Back to Index](#)



## MOU

### Gansons Ltd





**G**

**Research:**

a. Gansons and ICP will work together on joint research projects in areas of mutual interest. The objectives and scope of the projects would be as follows

**Background:**

Gansons Ltd. India and ICP intend to do collaborative projects using Gansons' machines. The main purpose will be to explore the innovations of these machines studying process parameters in product development.

**Project Objectives:**

ICP team will carry out a literature search for all the possible information that is relevant for formulation development using the machines. Based on the preliminary search, ICP team will work out the strategy for development and optimization of pharmaceutical formulations. Development of the formulation will start after approval and confirmation from Gansons that the proposed strategy is acceptable.

**Project Scope:**

Experimental work will be jointly undertaken at Gansons and ICP. The scope of activities involved is as follows:


- Formulation review and feasibility review/ proposal of strategy for formulation development.
- Literature summary along with formulation strategy will be submitted by ICP to Gansons who will approve of the strategy after considering status.
- Gansons will organise to procure required quantities of API, standards and impurities, etc. from the selected source (Included in Project Cost).
- Formulation Development trials for selection of variant formulations.
- Development of analytical methods for assay of the dosage form.
- Development of dissolution method.
- Preparation of Product Development Reports, Master Manufacturing Formula, Optimization of trials, Analytical testing instructions, etc.


**Terms & Conditions:**

- Excipients will not be analysed by the students but the same will be used based on COA of the manufacturer.
- Cost of analysis at external laboratory (for XRD, Malvern, TGA, DSC, GC, etc), if required, will be charged to Gansons and the analysis will be co-ordinated and managed by ICP.
- The work carried out by ICP Research and Gansons will be for research purpose only.

19

*[Handwritten signatures]*





**G**

**NON-DISCLOSURE AGREEMENT**

THIS NON-DISCLOSURE AGREEMENT (this "Agreement") is made and entered into as of between Gansons Ltd., Mumbai and Indira College of Pharmacy(ICP), having its education setup at Niramay, 5, No 89/2A, New Pune Mumbai Highway, Tathwade, Pune, Maharashtra - 411033.

**Purpose:** Gansons and ICP wish to explore opportunities in Training, Student Corporate Placement, Research, & consultancy of mutual interest and in connection with this opportunity wishes to execute this Non-Disclosure Agreement ("NDA").

**1. Confidential Information:** Confidential information means any information disclosed to by one party to the other, either directly or indirectly in writing, orally or by inspection of tangible or intangible objects, including without limitation documents, business plans, source code, software, hardware, application and uses of hardware and software, documentation, financial analysis, marketing plans, customer names, customer list, customer data. Confidential Information may also include information disclosed to a party by third parties at the direction of a Disclosing Party. Confidential Information shall not, however, include any information which the Receiving party can establish (i) was publicly known and made generally available in the public domain prior to the time of disclosure; (ii) becomes publicly known and made generally available after disclosure through no action or inaction of Receiving Party; or (iii) is in the possession of Receiving Party, without confidentiality restrictions, at the time of disclosure by the Disclosing Party as shown by Receiving Party's files and records immediately prior to the time of disclosure. The party disclosing the Confidential Information shall be referred to as "Disclosing Party" in the Agreement and the party receiving the Confidential Information shall be referred to as "Receiving Party" in the Agreement.

**2. Non-use and Non-disclosure:** The Receiving Party agrees not to use any Confidential Information for any purpose except to evaluate and engage in discussions concerning a potential business relationship between the parties hereto. Receiving Party agrees not to disclose any Confidential Information to third parties or to its employees, except to those employees who are required to have the information in order to evaluate or engage in discussions concerning the contemplated business relationship. The Receiving Party shall not reverse engineer, disassemble or decompile any prototypes, software or other tangible objects which embody the Disclosing Party's Confidential Information and which are provided to the Receiving Party hereunder.

**3. Maintenance of Confidentiality Information:** The Receiving Party agrees that it shall take all reasonable measures to protect the secrecy of and avoid disclosure and unauthorized use of the Confidential Information. Without limiting the foregoing, Receiving Party shall take at least those measures that Receiving Party takes to protect its own most highly confidential information and shall have its employees, if any, who have access to Confidential Information sign a non-use and non-disclosure agreement in content substantially similar to the provisions hereof, prior to any disclosure of Confidential Information to such employees. The Receiving Party shall not make any copies of Confidential Information unless the same are previously approved in writing by the Disclosing Party. The Receiving Party shall reproduce the Disclosing Party's proprietary rights notices on any such approved copies, in the same manner in which such notices were set forth in or on the original. The Receiving Party shall immediately notify the Disclosing Party in the event of any unauthorized use or disclosure of the Confidential Information.

**4. No Obligation:** Nothing herein shall obligate either party to proceed with any transaction between them, and each party reserve the right, in its sole discretion, to

*myk* *D. D. D.*

G

terminate the discussions contemplated by this Agreement concerning the business opportunity.

**5. No Warranty:** All confidential information is provided "as is". Neither party makes any warranties, express, implied or otherwise, regarding its accuracy, completeness or performance.

**6. Return of Materials:** All documents and other tangible objects containing or representing Confidential Information and all copies thereof which are in the possession of Receiving Party shall be and remain the property of the Disclosing Party and shall be promptly returned to the Disclosing Party upon the Disclosing Party's request.

**7. No License:** Nothing in this Agreement is intended to grant any rights to either party under any patent, mask work right or copyright of Company, nor shall this Agreement grant the receiving Party any rights in or to Confidential Information except as expressly set forth herein.


**8. Term:** This Agreement shall survive for a period of 2 years (renewable and extended up to 3 years) from the date of disclosure of the Confidential Information.


**9. Remedies:** The Receiving Party agrees that any violation or threatened violation of this Agreement will cause irreparable injury to the Disclosing Party, entitling the Disclosing Party to obtain injunctive relief in addition to all legal remedies.

**10. Miscellaneous:** This Agreement shall bind and insure to the benefit of the parties hereto and their successors and assigns. This document contains the entire agreement between the parties with respect to the subject matter hereof. Any failure to enforce any provision of this Agreement shall not constitute a waiver thereof or of any other provision hereof. This Agreement may not be amended, nor any obligation waived, except by a writing signed by both parties hereto. The parties have executed this Nondisclosure Agreement as of the date first above written.

For Gansons Ltd For Indira College of Pharmacy

Mr Samik Sen Dr. (Mrs.) Anagha Joshi  
 AVP - Marketing Principal  
 Date: Date:

*On behalf of Samik Sen*  
  
 Vishakha. Ranaol  
 Executive - Marketing



**SUMMARY**

*Shree Chanakya Education Society's*  
**Indira College of Pharmacy, Pune**

*"Redefining Pharmacy Education"*

**NAAC: B++**

Approved by PCI, AICTE, New Delhi, Affiliated to SPPU & MSBTE, Recognized by Govt. of Maharashtra

**SUMMARY**

Title: Activities carried out under MOU ( Gansons)			
S.No.	Name of the Activity	Topic	Detail
1	Research Project	Formulation and evaluation of Ibuprofen granules in High shear Mixer granulator and supergran	Collaborative research project done by Dhanashree Bhondve, M. Pharm student
2	Poster Presentation	To compare quality of granules of ibuprofen obtained from super gran and rapid mixer granulator	19th International symposium on "Advances in Technology and Business Potential of Novel Drug Delivery System" organized by CRS IC
3	Research Paper	Development and evaluation of taste masked dry syrup formulation of potassium chloride	Kulkarni M et al, 5:1, AAPS Open, 2019
4	Poster Presentation	Development and evaluation of taste masked dry syrup formulation of potassium chloride	National seminar on "Excipients: The Key Drivers in Formulation Success"



*Anagha M Joshi*

**Dr. Anagha M Joshi**  
**PRINCIPAL**  
 (Principal)  
**Indira College of Pharmacy**  
**Tathawade, Pune - 411 033**





Research Projects

Criterion - III– Research, Innovations & Extension

SSR

2022

Research Projects

**Gansons**  
Better Solutions Since 1927

Ref: FAC/ADMIN/E419  
Date: 22/10/2019


**TO WHOMSOEVER IT MAY CONCERN**


This is to certify that Ms. Dhanashree Bhandve has undertaken her M.Pharm research project titled "Formulation and evaluation of Ibuprofen granules in High shear mixer granulator and SuperGran™" at Gansons Private Ltd. under the able guidance of Mr. Brijesh Vishwakarma.


This project was done in collaboration with Dr. Madhur Kulkarni, Associate Professor, SCES's Indira College of Pharmacy. The project was commenced on 2<sup>nd</sup> July 2018 and completed on 20<sup>th</sup> March 2019. During this tenure Dhanashree was found to be sincere and hardworking and her performance was satisfactory.

We wish her success in all her future endeavours.

Thanking you,

For GANSONS PRIVATE LIMITED  
  
MRS. A. FARIA  
SR. VICE PRESIDENT – HR & ADMIN.



  
PRINCIPAL  
Indira College of Pharmacy  
Lathawade, Pune - 411 033

Gansons Pvt. Ltd. | CIN: U24110MH19477TC005906 | Tel: +91 22 25868059/8084/8086 | Email: hr@gansons.com  
152/158A, Aaher Camp Road, Kothrud, Sandos Baug, Thane (W) - 400 507 Maharashtra (India)

SCES'S Indira College of Pharmacy, Pune

Poster Presentation

Criterion - III– Research, Innovations & Extension | SSR | 2022

Poster Presentation

P-140

**TO COMPARE QUALITY OF GRANULES OF IBUPROFEN OBTAINED FROM SUPER GRAN™ AND RAPID MIXER GRANULATOR**

**Bansode K., Kulkarni M., Bhone D.**  
Niramay, S.No.89/2A, SCES Indira college of Pharmacy, New Pune Mumbai Highway,  
Tathawade, Pune, Maharashtra-411033, India  
Email: kiranbansode99@gmail.com

**Keywords:** Ibuprofen, Super Gran™, Rapid Mixer Granulator

**Introduction:** Super Gran™ is a mixer cum granulator developed and patented by Gansons Ltd which is characterized by presence of multiple stacked impeller blades and two scrapers. The special design of the granulator is expected to enhance the speed of dry mixing, wet granulation and wet milling compared to rapid mixer granulator. This technology is expected to enhance the uniformity of granulation.

**Aim:** The aim of the present study was to compare quality of granules of ibuprofen (ibu) prepared in Super Gran™ and rapid mixer granulator (rmg).

**Objectives:** 1. To prepare ibu granules using various diluents and granulating agents in Super Gran™ and rmg 2. To compare the granules obtained from both the granulators 3. To compare tableting characteristics of both the granules **Methodology:** Ibu granules were prepared by wet granulation technique using various trial compositions.(Table 1)For each composition, dry mixing and wet granulation were carried out in rmg (Bectochem)and Super Gran™. The resulting granules were compared for flow properties, proportion of fines and morphology. The granules were compressed into tablets using 12mm s/c circular plain punches (Rimek, Karnavati). The tablets were evaluated for appearance, weight variation, hardness, friability, disintegration time. *In vitro* release profiles (conducted as per USP monograph) were compared using Student's t test. 2<sup>2</sup> Full Factorial design was used for optimization trials of ibu tablets in both SuperGran™ and rmg. Independent variables chosen were concentration of binders (maize starch and PVP K-30). The response variables were disintegration time (<3 mins) and *in vitro* release (not less than 80% within 60 mins). Total 7 trial runs (A1-A7 and S1-S7) suggested by Design Expert Software® (Version 11) were processed in both the granulators, granules were compressed and the tablets were evaluated for all the earlier mentioned parameters.

Ingredients	Quantity in mg/tab					Binder	Disintegration			
	R1/S1	R2/S2	R3/S3	R4/S4	R5/S5		R1/S1	R2/S2	R3/S3	R4/S4
						Povidone K-30	27.27	-	-	-
						Starch maize	-	33	-	43.7
						Purified water	9.4	9.4	9.4	9.4
Dry Milling						Starch dried	-	40	-	40
Ibuprofen	400	400	400	400	400	Avicel 200	2.5	7.65	-	7.41
Lactose	26	-	115	-	-	Hydroxypropyl methylcellulose	20.91	20.92	20.93	20.94
Microcrystalline Cellulose	33	-	-	-	-	Starch acid	-	1.50	-	1.50



*myeh*  
**PRINCIPAL**  
Indira College of Pharmacy  
Tathawade, Pune - 411 033



Research Paper



Research Paper

Nikam et al. *AAPS Open* (2019) 5:1  
 https://doi.org/10.1186/s41201-019-0033-z

AAPS Open

RESEARCH Open Access

Development and evaluation of taste masked dry syrup formulation of potassium chloride

Madhur Kulkarni<sup>1\*</sup>, Bijesh Vishwakarma<sup>2</sup>, Samik Sen<sup>3</sup>, Sandhya Anupam<sup>1</sup> and Abhinav A Dixit<sup>3</sup>

**Abstract**  
 Potassium chloride (KCl) syrup is widely used for the oral treatment of the hypokalemia. However, it is associated with unacceptable taste. In the present study, we sought to develop a palatable and easy to incorporate KCl dry syrup as a commercially viable alternative to currently available KCl syrup. We explored the potential of Eudragit E100 as a taste-masking polymer to coat and improve the palatability of the KCl. With the help of fluid bed processor, KCl was coated with the solution containing varying amounts of Eudragit E100 (4, 6, 10 and 15%). Coating with 10% polymer solution enabled optimal fluid bed processing, higher entrapment of the KCl (81%) and better in vitro release profile in 0.1 N HCl and pH 6.8 phosphate buffer. A dry syrup formulation containing Eudragit E100 coated KCl with good physical and chemical stability in dry and reconstituted state was developed. The palatability of the optimized formulation and commercially available KCl syrup was evaluated using the Electronic Taste Sensing Machine. The developed formulation showed ~2-fold better taste masking compared to the commercial KCl syrup. Thus, present investigation describes the development of an effective alternative to the current KCl syrup that can offer better palatability, stability and patient compliance.

**Keywords:** Taste masking, KCl, Eudragit E100, Fluid bed processing, Electronic taste sensing machine

**Introduction**  
 Hypokalemia is characterized by the potassium depletion from the body. Patients receiving diuretic treatment, those suffering from diabetic ketoacidosis or primary and secondary hyperaldosteronism often experience hypokalemia (Cohn et al., 2003). Potassium depletion due to these causes is usually accompanied by a concurrent loss of chloride. Potassium chloride (KCl) is an electrolyte of choice for the treatment of hypokalemia as it can replace potassium as well as chloride ions in the patients experiencing hypokalemia (Shen, 1996; Gossard, 1994). Patients with hypokalemia typically require a dose between 40 and 100 mEq of potassium per day. The US FDA has approved a number of immediate and extended release KCl formulations which contain a relatively high amount of KCl (600–1800 mg) to meet the daily requirement (Mittal et al., 2017). Due to a relatively high dose of KCl, these formulations are bulky and are difficult to swallow especially for the pediatric and geriatric population.

Another issue with oral KCl therapy is its very unacceptable taste which often leads to nausea and vomiting. Furthermore, sudden availability of large dose of KCl also leads to gastric irritation which further exacerbates nausea and vomiting (Mehrotra et al., 1983). The film coated tablets and extended release capsule and tablet formulations minimize this side effect (Wu et al., 2003; Graham et al., 1990; Chang and Radwin, 1997; Kumar et al., 2011). However, these formulations are not very suitable for pediatric and geriatric patients. Furthermore, in India, only KCl syrup and solution are available to the patients (CMS, 2017) and these formulations have very unacceptable taste. Here, we report the development of KCl dry syrup with improved palatability. To improve the palatability of KCl, we directly coated pure KCl crystals with Eudragit E 100, a pH sensitive anionic alkyl methacrylate copolymer by means of fluid bed processing. This strategy

\* Correspondence: madhurkulkarni@indira.ac.in  
 Department of Pharmaceutics, SCES/Indira College of Pharmacy, BDA, Indira, Sion, Marol Bhayli Pune Highway, Tathawade, Pune, Maharashtra 411033, India  
 Full list of author information is available at the end of the article

© The Author(s). 2019 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Springer Open



*M. Kulkarni*  
 PRINCIPAL  
 Indira College of Pharmacy  
 Tathawade, Pune - 411 033

SCES'S Indira College of Pharmacy, Pune

Poster Presentation 2

Criterion - III

SSR

2022



Poster Presentation

**DEVELOPMENT AND EVALUATION OF TASTE MASKED DRY SYRUP FORMULATION OF POTASSIUM CHLORIDE (KCL)**

**Gadre T., Tandale K., Kulkarni M., Anupram S., Vishwakarma B.**  
 Niramay, S.No. 89/2 A, SCES Indira college of Pharmacy, New Pune Mumbai Highway, Tathawade, Pune, Maharashtra-411033, India  
 Email : tjtejasri2522@gmail.com

**Aim:** The aim of the present study was to develop and evaluate taste masked dry syrup formulation of KCl.

**Objectives –**

1. Coating of KCl with Eudragit E 100, a pH sensitive amino alkyl methacrylate copolymer by means of fluid bed process
2. Development of dry syrup formulation of coated KCl
3. Comparison of developed formulation with marketed syrup for *in vitro* dissolution parameters and taste masking aspect.

**Methodology:** Fluid bed coating of KCl was performed using 4, 6, 10 and 15% coating solutions of Eudragit E100. Process parameters like spray rate, inlet air temperature, bed temperature and atomizing air pressure were optimized. The 4 lots of drug coated using solutions containing 4%, 6%, 10% and 15% of Eudragit E 100 were termed as C1, C2, C3 and C4 respectively. They were subjected to evaluation of microscopy, particle size analysis, flow properties, entrapment efficiency and dissolution studies in 0.1N HCl and pH 6.8 phosphate buffer.

Reconstituted formulation was subjected to organoleptic evaluation, redispersibility, sedimentation volume, assay and *in vitro* dissolution in both 0.1N HCl and 6.8 phosphate buffer on day 1, 2, 3 and 7 of reconstitution. The developed formulation and the marketed syrup formulation were compared for their dissolution behavior and the palatability aspect using electronic taste sensing machine. Optimized formulation was filled in clear glass bottles, capped and subjected to accelerated conditions of 40±2 °C and 75% ±5% RH.

**Results:** Coating with 10% polymer solution (composition C3) enabled optimal fluid bed processing, higher entrapment of the KCl (81%) and better *in vitro* release profiles in 0.1N HCl and pH 6.8 phosphate buffer. Whereas, coating with higher concentration of polymer resulted in sticking and agglomeration of particles. *In vitro* release in 0.1N HCl was more than 95% within 30 minutes throughout the 7 days. Marketed syrup formulation upon subjected to dissolution studies in 0.1N HCl and pH 6.8 phosphate buffer showed complete dissolution of drug within 5 minutes unlike the



*Myel*  
**PRINCIPAL**  
 Indira College of Pharmacy  
 Tathawade, Pune - 411033.

SCES'S Indira College of Pharmacy, Pune

[Back to Index](#)

MOUSciformix

महाराष्ट्र MAHARASHTRA

2017

SC 919326



श्री. सु. का. पाटील

## MASTER COLLABORATION AGREEMENT

This MEMORANDUM OF AGREEMENT made at Pune, on this 8 June, day Thursday of 2017, between Sciformix Technologies Pvt. Ltd. having its registered office at Akruti Softech Park, 2<sup>nd</sup> Floor, Road no. 21, MIDC, Andheri (East), Mumbai 400093 (hereinafter referred to as 'Sciformix' in brief) and Indira college of Pharmacy, Pune having its registered office at 89/2A, Niramay New Mumbai-Pune Highway, Tathawade 411033.

WHEREAS, Sciformix is a leading provider of drug safety services for several biopharmaceutical and healthcare companies. With expansion of its PV services, Sciformix recognizes the need to offer training programs in PV with a view to build capacity in PV in the country. With this objective, Sciformix is collaborating with ICP to establish a certificate course in PV and to conduct it.

Confidential

Page 1 of 7

**WHEREAS**, ICP is a recognized teaching institute affiliated to Savitribai Phule Pune University and offers undergraduate and postgraduate courses in pharmaceutical sciences, including the Pharm D. program. It is aware of the growing importance of drug safety and is interested in offering training in this subject.

**NOW, THEREFORE**, in consideration of the promise and mutual covenants herein contained and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, it is mutually covenanted and agreed by and between the parties here as it follows :

Sciformix and ICP are interested in collaborating to offer a certificate course in PV and Medicinal Safety (PVMS) to students of Pharmacy, Medicine and Biological Sciences.

**A. Responsibilities:**

1. ICP will be responsible for conducting the course through Dept of Pharmacology. ICP will be responsible to let other colleges in the vicinity know about PV school and in turn spread awareness to the eligible students. The course venue will be ICP, Wakad, Pune.
2. Certificates will be issued jointly by ICP and Sciformix.
3. Sciformix will be responsible for syllabus design, developing the course content and will assume most of the responsibility for training. Sciformix will continue to be responsible for ensuring timely updates to the course content as regulations evolve and as there are changes in PV practice. Sciformix will be responsible for hands-on training on safety database for the students as well as participate in assessment of students at the time of admission and assume responsibility of assessment at the end of the course.

4. ICP's assigned staff will be course in-charge and will assume responsibility for admissions, promotion, administration and overall conduct of the course.
5. A governing body comprising of representatives of Sciformix and ICP will be formed. It shall consist of three representatives each from Sciformix and from ICP.
6. ICP agrees that Sciformix has an exclusive right on the study material that has been developed and ICP cannot use the material unless and until the explicit written permission has been granted by Sciformix.
7. ICP agrees to pay honorarium to the faculty members as per the agreed compensation rate (annexure 1.1) within 1 week of the session and to pay 50% advance of complete fees to Sciformix and the final settlement of accounts will be completed at the end of each batch
8. Sciformix agrees to share 50% of the surplus (profit) with ICP
9. In the event of losses both the parties will share the losses equally
10. ICP agrees that unless and until definite agreements between them for establishment of the PV course are finalized and signed, neither party will be under any legal obligation whatsoever with respect to such arrangements beyond the provision of this MOU.

#### **B. Expenditure and Payments**

1. Sciformix has spent about Rs 9,00,000/- (Nine lakhs only) towards study material development. Which will be recovered by spreading over four batches, with recovery of Rs 2,25,000/- (Rupees two lakhs twenty five thousand ) after each batch for four consecutive batches. (Annexure 1.1)
2. Expenses incurred for brochure printing, promotion of the course will shared equally by both the parties. (Annexure 1.1)

3. Sciformix will charge Rs 25,000/- for Argus data base facilitation per batch (Annexure 1.1)
4. ICP will be paid Rs 60,000/- towards rent and utilities per batch (Annexure 1.1)
5. Sciformix will charge Rs 60,000/-towards pre-selection interviews and Rs 30,000/-towards administration of examination and correction of papers.(Annexure 1.1)
6. ICP agrees to pay Sciformix 50% advance and the accounts will be settled after each batch
7. Sciformix agrees to share 50% profit with ICP

#### **C. Term of Agreement**

1. The term of this Agreement shall be for a period of three years commencing on the effective date, this Agreement shall be automatically renewed for successive three (3) year periods. However, this Agreement shall be reviewed annually by consent of both the parties for its performance.

#### **1) Relationship of the Parties**

1. Sciformix and ICP are independent parties. Both parties agree that their relationship is that of an independent collaborating parties and not of an employer and employee.
2. Neither party shall have express or implied rights nor the authority to assume or create any obligation or responsibility on behalf of or in the name of the other party by reason of this Agreement, except as provided in this master collaborative agreement.
3. It is understood that Sciformix and ICP shall exercise no control over the activities and operations of each other.



4. It is understood that the employee(s) of one party shall not be considered to be employee(s) of the other party and neither party shall enter into any contract or agreement with a third party which purports to obligate or bind the other party.
5. It is agreed that Sciformix can enter into agreement with any other person/institution/party or any legal entity for PV school and any similar capacity building activity during the subsistence of agreement with ICP

#### **D. Confidentiality**

1. The parties hereto recognize and agree that due to the complex and competitive nature of the business, the confidentiality of information concerning both parties is of critical importance. Either party shall not, either during or after the term of this Agreement, disclose to any third party any confidential information and information relating to the work or the business of either party without the written consent of either party. ICP agrees that it shall not during, or at any time after the termination of this Agreement, directly or indirectly disclose or use any study material for any reason whatsoever, without the prior written consent of Sciformix in each instance, provided that the following disclosures and uses shall be permitted hereunder.
  - a. Information may be furnished to any licensing authority or government agency.
  - b. Information may be supplied pursuant to legal process and
  - c. Information may be reviewed by Sciformix accountants and professional advisors.

**E. Compensation**

1. In consideration of the provision this "collaboration agreement" Sciformix agrees to share 50% of the profit with ICP. (Annexure:1.1)

**F. Termination of Agreement**

1. This Agreement shall be terminated by mutual agreement by giving thirty (30) days prior written notice by either party provided there is no ongoing batch of students pending course completion.

**G. Jurisdiction**

This Agreement has been accepted & executed by the parties at Pune, State of Maharashtra, India and it has been agreed to between the parties hereto that all the covenants terms & conditions hereof shall be observed and performed at Pune. Hence it is agreed that if any dispute arose between the parties in any way relating to this Agreement shall have jurisdiction to the Pune Courts only.

**H. Arbitration**

All the disputes, differences and/or claims arising out of this agreement whether during its subsistence or thereafter shall be settled by Arbitration in accordance with the Provisions of Arbitration & Conciliation Act – 1996 or any statutory amendments thereof and shall be referred to the Sole Arbitration of an Arbitrator nominated by the Chief Executive Officer of THE COMPANY. The award given by such Arbitrator shall be final and binding on both the parties to this Agreement. It is a term of this Agreement that in the event that such an Arbitrator to whom the matter has been originally referred to dies or is unable or unwilling to act for any reason, the Chief Executive Officer of the Company at the time of such death of the Arbitrator or his inability or his inability or unwillingness to act as arbitrator,

shall appoint another person to act as Arbitrator. Such person shall be entitled to proceed with the reference from the stage at which was left by his predecessor.


**I. Permission to use company specific Information or Statement**

This authorization shall extend only to Sciformix newsletters and / or other publications that inform the industry of Sciformix' business activities.

**J. Use of Party's Name and Logo.**

No party shall, without the prior written consent of the other party, use in advertising, publicity, or otherwise, the name, trademark, logo, symbol, or other image of the party.


**IN WITNESS WHEREOF**, the parties hereto have the authority to bind the party that they represent and have caused this Agreement to be duly executed in their respective names.

Signature : 

Name : Dr Chitra Lele Ph.D.

Title : Chief Scientific Officer

Date : 22-JUNE-2017

Signature : 

Name: Dr Anagha Joshi

Title : Principal

Date : 9/7/17

Confidential

Page 7 of 7

## SUMMARY



Shree Chanakya Education Society's

### Indira College of Pharmacy, Pune

"Redefining Pharmacy Education"

**NAAC: B++**

Approved by PCI, AICTE, New Delhi, Affiliated to SPPU & MSBTE, Recognized by Govt. of Maharashtra

#### SUMMARY

Title: Activities carried out under MOU (Sciformix)			
S.No.	Name of the Activity	No. of the students	Class
1.	Certification Course in Pharmacovigilance Training Programme with Argus orientation (2017-2018)	18	Final Year B. Pharm
2.	Placement	6	Final Year B. Pharm



Dr. Anagha M Joshi

**PRINCIPAL**


(Principal)  
Indira College of Pharmacy  
Tathawade, Pune - 411 033



Certification Course



*Shree Chanakya Education Society's*  
**INDIRA COLLEGE OF PHARMACY, PUNE**  
*"Redefining Pharmacy Education"*



*M. Joshi*  
PRINCIPAL  
Indira College of Pharmacy  
Tathawade, Pune - 411033.



## Offer Letter



*Shree Chanakya Education Society's*  
**Indira College of Pharmacy, Pune**  
*"Redefining Pharmacy Education"*

**NAAC: B++**

Approved by PCI, AICTE, New Delhi, Affiliated to SPPU & MSBTE, Recognized by Govt. of Maharashtra

June 1, 2018

Mr. Mohan Lachchharam Chaudhary  
 Flat no-15, Mahavir Nagar H building  
 Opposite to Anandi Dining Hall  
 Singhd Road Pune-51

**Subject: Offer of employment**

Dear Mr. Chaudhary:


Thank you for the time you spent interviewing with us recently. We are pleased to inform you that we are satisfied with your qualifications and experience. Consequently as per our discussions, we would like to confirm our offer to you in our organization as detailed below:

1. Your designation will be Trainee Safety Data Analyst and you will be mainly posted in Pune. This offer is subject to clearance and submission of your final year result by end of July 2018
2. Your basic salary will be Rs. 7,000 (Rupees Seven Thousand Only) per month. Your fixed gross annual cost to the company (CTC) would be Rs. 240,000 (Rupees Two Lakh Forty Thousand Only). Please refer Compensation Particulars below.
3. The performance linked bonus is an indicative amount and will vary based on your performance rating for the year.
4. Since the company has made significant investment in training you, you will be expected to serve a minimum of 18 months with the company effective your start date of employment so that the knowledge gained remains within the Company for a substantial period of time. Should you decide not to continue the employment, you will be liable to pay the company the all expense incurred by the Company for your training.
5. A broad description of the roles and responsibilities will be detailed in the job description which will be given to you upon joining.
6. You will be joining us on June 4, 2018.

Particulars	Monthly	Annual
Basic Salary	Rs 7,000	Rs 84,000
City Compensatory Allowance	Rs 5,000	Rs 60,000
Basket of Allowances*	Rs 6,824	Rs 81,888
<b>Compensation (A)</b>	<b>Rs 18,824</b>	<b>Rs 225,888</b>
Employer's Contribution to Provident Fund		Rs 10,080
Employer's Contribution to Gratuity		Rs 4,038
<b>Compensation (B)</b>		<b>Rs 14,118</b>
Gross Fixed CTC		<b>Rs 240,000</b>
Performance Linked Bonus (Variable)		Rs 30,000
Gross Annual Total		<b>Rs 270,000</b>
+ Tax exempt to the extent of receipts furnished		
++ Tax exempt to the extent of amount prescribed under Indian Income Tax Act		

Principal

Indira College of Pharmacy  
 Tathawade, Pune - 411033.





Shree Chanakya Education Society's  
**Indira College of Pharmacy, Pune**  
 "Redefining Pharmacy Education"

**NAAC: B++**

Approved by PCI, AICTE, New Delhi, Affiliated to SPPU & MSBTE, Recognized by Govt. of Maharashtra

Children Education Allowance, House Rent Allowance, Leave Travel Allowance		
Note: Above allowances are tax-exempt subject to fulfillment of Income Tax Rules		
<b>Additional Benefits:</b>		
Medical Insurance Premium (For Self, Spouse & Two Children)		Rs 6,486
Accident Insurance Premium		Rs 530

Please return a signed copy to us confirming your acceptance of this offer. Please be advised that you are signing the offer letter at your own will. This offer shall remain valid only until June 2, 2018.

At the time of reporting, you are required to bring along with you the following documents to be handed over to us. Your appointment will be subject to receipt of these documents by Sciformix:

- An unconditional relieving letter from your present employer, in case you are employed. Please obtain your PF/EPF number from your present employer.
- Two passport size photographs and photocopies of certificates in proof of your age (preferably passport copy), qualifications and experience.

Full effect to the terms and conditions shall be through an employment agreement containing terms and conditions of employment that will be given to you upon your joining. You will be required, as a condition of your employment with Sciformix, to agree to Confidential Information, Non-Competition, Non-Solicitation and Assignment of Inventions as defined in the mutually agreed upon Employment Agreement.

Sincerely,

Authorized Signatory  
 For Sciformix Technologies Private Limited

I hereby accept your offer of employment as Trainee Safety Data Analyst and will report for work on \_\_\_\_\_

*Mech*  
 PRINCIPAL  
 Indira College of Pharmacy  
 Tathawade, Pune - 411033.

Signature: \_\_\_\_\_  
 Mohan Chaudhary

Date: \_\_\_\_\_



[Back to Index](#)

## MOU

### Electrolab Pvt Ltd

Date: 10/05/2017

#### Memorandum of Understanding between Electrolab (India) Pvt.Ltd and Indira College of Pharmacy

Electrolab and SCES' Indira College of Pharmacy (ICP) hereby agree to enter into a Memorandum of Understanding (MoU) for academic and professional collaboration with the purpose of mutual benefit. Electrolab has been in the business of pharmaceutical testing equipment for more than 30 years. ICP was established in 2006 and since then offers the courses of B.Pharmacy and M.Pharmacy. Both parties agree that giving exposure to the students to cutting edge technologies and practical projects will enable students to secure jobs as well as pursue entrepreneurship options. Both parties agree to the following terms

#### **Placements and Corporate Relations:**

- a. Both organizations will work closely to come up with models of regular engagement between ICP students and faculties and Electrolab trainers, developers and project managers.
- b. Electrolab will allow ICP undergraduates and post-graduates and faculty to visit their lab and attend technology conferences and events that Electrolab organizes for exposure and practical knowledge.
- c. Looking at the expansion plan of Electrolab large pool of skilled manpower at different levels for small projects or for final hiring purpose will be required in the coming years. Electrolab will offer training and internship to the students of ICP for a period of 6 months to one year from commencement of the project and as per their performance may offer placement. Based on the duration of the project, a consolidated stipend, as mutually decided by Electrolab and ICP will be paid by Electrolab.

#### **Research:**

- a. Electrolab and ICP will work together on joint research projects in areas of mutual interest. The projects designed or conceptualized by ICP faculty/ students will be executed partly at Electrolab and partly in the college after approval of the research proposal by Electrolab. Vice versa will also be possible.
- b. The research work undertaken jointly by ICP and Electrolab will be published in reputed journals under the ownership of both the parties. In case of patentable research, both the parties would be the applicants of IPR and will share the benefits on equal basis.
- c. Library and Lab facilities will be provided by ICP as and when required to Electrolab employees on a prior notice for the research work. For the use of sophisticated instruments and equipment, no charges will be applicable.
- d. Electrolab will allow the students and faculty of ICP to use sophisticated instruments and equipment on a prior notice for the research work. This kind help extended by Electrolab will be duly



acknowledged by the students and faculty in their research publications and dissertation. The consumables such as solvents, reagents etc. will be procured by ICP.

- e. Electrolab may donate some fabricated equipment and parts of dissolution testing apparatus to ICP for research purpose.

**f. Consultancy:**

- a. ICP believes in inviting and involving Corporate Professionals for Board of Advisors, Guest Lectures, Workshops, Seminars and similar events for which expert/s are required for enhancing knowledge, skills and attitude of Faculty & Students. To achieve this objective, whenever possible, Electrolab will allow their professionals to visit ICP. ICP will also allow their faculty to visit Electrolab for sharing their knowledge and expertise in the area of interest for Electrolab.

**g. Training:**

- a. Electrolab and ICP will conduct Faculty Development Programmes (FDP), Refresher Courses at ICP or Electrolab for which Electrolab will charge appropriately based on the number of participants in areas of mutual interest as mutually decided by the Director - Electrolab and Principal - ICP.
- b. Electrolab will conduct meetups/events/trainings at ICP. Electrolab may charge external participants some participant fees. ICP students shall be having a right to preferred discounts such as 20 % or 30 % in such meetups/events/trainings and the revenue will be split 70:30 between Electrolab/ICP.
- c. All the promotional activities will be managed and marketing/faculty costs for meetups/events/trainings at ICP shall be borne by Electrolab whereas ICP shall bear the infrastructure cost, admin costs and incidentals. Both parties will inform via email of the events and visits and seek prior permission from Principal - ICP and Director of Electrolab.

**Contact Persons**

Dr. (Mrs.) Madhur Kulkarni will be the contact person for ICP to initiate, manage or execute any joint activities between ICP and Dr. Neelam Sayed will be the contact person for Electrolab.



By: Director - Electrolab

Name: Mr. Aditya Marfatia



By: Principal - ICP

Name: Dr. (Mrs.) Anagha Joshi

Date: June 13, 2017

Date: 8/11/17

**NON-DISCLOSURE AGREEMENT**

THIS NON-DISCLOSURE AGREEMENT (this "Agreement") is made and entered into as of between Electrolab, Navi Mumbai and Indira College of Pharmacy(ICP), having its education setup at Niramay, S.No 89/2A, New Pune Mumbai Highway, Talwade, Pune, Maharashtra – 411033. Purpose: Electrolab And ICP wish to explore Opportunities in Training, Student Corporate Placement, Research, & consultancy of mutual interest and in connection with this opportunity wishes to execute this Non-Disclosure Agreement ("NDA").

- 1. Confidential Information:** Confidential information means any information disclosed by one party to the other, either directly or indirectly in writing, orally or by inspection of tangible or intangible objects, including without limitation documents, business plans, source code, software, hardware, application and uses of hardware and software, documentation, financial analysis, marketing plans, customer names, customer list, customer data. Confidential Information may also include information disclosed to a party by third parties at the direction of a Disclosing Party. Confidential Information shall not, however, include any information which the Receiving party can establish (i) was publicly known and made generally available in the public domain prior to the time of disclosure; (ii) becomes publicly known and made generally available after disclosure through no action or inaction of Receiving Party; or (iii) is in the possession of Receiving Party, without confidentiality restrictions, at the time of disclosure by the Disclosing Party as shown by Receiving Party's files and records immediately prior to the time of disclosure. The party disclosing the Confidential Information shall be referred to as "Disclosing Party" in the Agreement and the party receiving the Confidential Information shall be referred to as "Receiving Party" in the Agreement.
- 2. Non-use and Non-disclosure:** The Receiving Party agrees not to use any Confidential Information for any purpose except to evaluate and engage in discussions concerning a potential business relationship between the parties hereto. Receiving Party agrees not to disclose any Confidential Information to third parties or to its employees, except to those employees who are required to have the information in order to evaluate or engage in discussions concerning the contemplated business relationship. The Receiving Party shall not reverse engineer, disassemble or decompile any prototypes, software or other tangible objects which embody the Disclosing Party's Confidential Information and which are provided to the Receiving Party hereunder.
- 3. Maintenance of Confidentiality Information:** The Receiving Party agrees that it shall take all reasonable measures to protect the secrecy of and avoid disclosure and unauthorized use of the Confidential Information. Without limiting the foregoing, Receiving Party shall take at least those measures that Receiving Party takes to protect its own most highly confidential information and shall have its employees, if any, who have access to Confidential Information sign a non-use and non-disclosure agreement in content substantially similar to the provisions hereof, prior to any disclosure of Confidential Information to such employees. The Receiving Party shall not make any copies of Confidential Information unless the same are previously approved in writing by the Disclosing Party. The Receiving Party shall reproduce the Disclosing Party's proprietary rights notices on any such approved copies, in the same manner in which such notices were set forth in or on the original. The Receiving Party shall immediately notify the Disclosing Party in the event of any unauthorized use or disclosure of the Confidential Information.
- 4. No Obligation:** Nothing herein shall obligate either party to proceed with any transaction between them, and each party reserve the right, in its sole discretion, to terminate the discussions contemplated by this Agreement concerning the business opportunity.
- 5. No Warranty:** ALL CONFIDENTIAL INFORMATION IS PROVIDED "AS IS". NEITHER PARTY MAKES ANY WARRANTIES, EXPRESS, IMPLIED OR OTHERWISE, REGARDING ITS ACCURACY, COMPLETENESS OR PERFORMANCE.
- 6. Return of Materials:** All documents and other tangible objects containing or representing Confidential Information and all copies thereof which are in the possession of Receiving Party shall be and remain the

property of the Disclosing Party and shall be promptly returned to the Disclosing Party upon the Disclosing Party's request.

7. **No License:** Nothing in this Agreement is intended to grant any rights to either party under any patent, mask work right or copyright of Company, nor shall this Agreement grant Receiving Party any rights in or to Confidential Information except as expressly set forth herein.

8. **Term:** This Agreement shall survive for a period of 1 year (renewable and extended up to 3 years) from the date of disclosure of the Confidential Information.

9. **Remedies:** The Receiving Party agrees that any violation or threatened violation of this Agreement will cause irreparable injury to the Disclosing Party, entitling the Disclosing Party to obtain injunctive relief in addition to all legal remedies.

10. **Miscellaneous:** This Agreement shall bind and inure to the benefit of the parties hereto and their successors and assigns. This document contains the entire agreement between the parties with respect to the subject matter hereof. Any failure to enforce any provision of this Agreement shall not constitute a waiver thereof or of any other provision hereof. This Agreement may not be amended, nor any obligation waived, except by a writing signed by both parties hereto. The parties have executed this Nondisclosure Agreement as of the date first above written.

[Electrolab] [ICP]

*Aditya Mahesh Marfatia* *Dr. (Mrs.) Anagha Joshi*

By: Director By: Principal

Name: Mr. Aditya Marfatia Name: Dr. (Mrs.) Anagha Joshi

Date: June 13, 2017 Date: 31/6/17

**SUMMARY**

Shree Chanakya Education Society's

**Indira College of Pharmacy, Pune**

"Redefining Pharmacy Education"

**NAAC: B++**

Approved by PCI, AICTE, New Delhi, Affiliated to SPPU &amp; MSBTE, Recognized by Govt. of Maharashtra

**SUMMARY**

Title: Activities carried out under MOU (Electrolab)				
S.No.	Name of the Activity	Year	Topic	Details
1	Research Projects	2017-2018	To develop rugged and reproducible drug release method for Acyclovir semisolid formulation using immersion cells	Collaborative Research project by Shrikant Potdar, M.Pharm student
2	Research Paper	2019-2020	In vitro release testing of Acyclovir topical formulations using immersion cell	Kulkarni, M et al, Assay & Drug Development Technology
3	Training Program	2017-2018	Principle and applications of Dissolution apparatus 3-7	Hands on training for F.Y. M.Pharm students and faculty
4	Training Program	2018-2019	Principle and applications of Dissolution apparatus 3-7	Hands on training for F.Y. M.Pharm students and faculty
5	Training Program	2019-2020	Principle and applications of Dissolution apparatus 3-7	Hands on training for F.Y. M.Pharm students and faculty
6	Training Program	2020-2021	Principle and applications of Dissolution apparatus 3-7	Hands on training for F.Y. M.Pharm students and faculty
7	Training Program	2021-2022	Principle and applications of Dissolution apparatus 3-7	M. Pharm
8	Poster presentation	2019	In vitro of acyclovir semisolid formulations using immersion cells. Study of effect of test and formulation variables	19th International Symposium of controlled release society-India, Chapter



PRINCIPAL  
Indira College of Pharmacy  
Tatwadade, Pune - 411 033



Shree Chanakya Education Society's

## Indira College of Pharmacy, Pune

"Redefining Pharmacy Education"

**NAAC : B++**

Approved by PCI, AICTE, New Delhi, Affiliated to SPPU & MSBTE, Recognized by Govt. of Maharashtra

				on Advances in Technology and Business Potentials of New Drug Delivery Systems
--	--	--	--	--

Dr. Anagha M Joshi

**PRINCIPAL**

Indira College of Pharmacy  
Tathawade, Pune - 411 033





Research Projects

Criterion - III

SSR

2022




**ELECTROLAB (India) PVT. LTD.**  
Plot No. EL 23/24, T.T.C. Electronic Zone, M.I.D.C. Mahape, Navi Mumbai - 400 710, INDIA. Tel. : +91-22-4161 3131 Fax : 91-22-4161 3199

To Whomsoever It May Concern

This is to certify that Mr. Shrikant Potdar has undertaken his M.Pharm research project titled "To develop rugged & reproducible drug release method for acyclovir Semi Solid Formulation using immersion cells" at Electrolab under the able guidance of Dr. Neelam Sayed. The project was commenced on 17 July 2017 and completed on Feb 2018. During this tenure Shrikant was found to be sincere and hard working and his performance was satisfactory.

For Electrolab (India) Pvt Ltd.

Mr. Amit Marfatia  
Managing Director



Principal  
Indira College of Pharmacy  
Tathawade, Pune - 411033.

SCES'S Indira College of Pharmacy, Pune



Research Paper



### In Vitro Release Testing of Acyclovir Topical Formulations Using Immersion Cells

Mohar Kulkarni,<sup>1</sup> Shikhar Hestor,<sup>2</sup> Abhijeet A. Dote,<sup>3</sup> and Ashya Marathe<sup>4</sup>

<sup>1</sup>Department of Pharmaceutics, Shree Chhatrapati Shivaji Maharaj Vastu Sangrahalaya, Pune, India  
<sup>2</sup>Department of Pharmaceutics, Shree Chhatrapati Shivaji Maharaj Vastu Sangrahalaya, Pune, India  
<sup>3</sup>Department of Pharmaceutics, Shree Chhatrapati Shivaji Maharaj Vastu Sangrahalaya, Pune, India  
<sup>4</sup>Department of Pharmaceutics, Shree Chhatrapati Shivaji Maharaj Vastu Sangrahalaya, Pune, India

#### INTRODUCTION

In vitro release testing (IVRT) is an important quality and performance parameter for evaluation of the topical semisolid formulations. Similar to the solid oral dosage forms, IVRT of semisolids can help during product development stages in identifying the critical formulation and manufacturing variables. The release profile of the active ingredients from the formulation allows for optimization of the physical characteristics of the formulation during product development. A well-established, discriminatory IVRT method can also provide support during the stages of clinical development by establishing same-dose active formulation changes are implemented during the course of clinical assessment. Besides aiding in product development, the IVRT can serve as a quality control tool to confirm batch-to-batch uniformity of the product. It helps in comparing the in vitro release profiles of test and reference products, though it is not expected to correlate or be predictive of in vivo bioavailability or bioequivalence. With the establishment of in vitro in vivo correlation by the developed method, the prediction of in vivo bioequivalence could also be possible.

#### ABSTRACT

The objective of the study was to revalidate the applicability of the immersion cells for the in vitro release testing (IVRT) of topical formulations by using marketed acyclovir 5% cream formulation (Cream 1) as a model. The method employing the immersion cells was optimized by studying the effect of variables, such as membrane type, media temperature and volume, agitation speed, and cell size, on acyclovir release from the formulation. The 8-hour formulation similar to the qualitative and quantitative composition of Cream 1 and the other trial formulations with variable compositions were prepared and studied by using the immersion cells. Various other brands of acyclovir topical formulations available in the Indian market were also subjected to IVRT by using the optimized method. An increase in the media temperature from 22°C to 37°C and the stirring speed from 50 to 100 to 150 rpm led to an increase in the drug release. As the immersion cell size increased (1.5, 2 and 4 cm<sup>2</sup> surface area), the release rate also increased. Nitrocellulose membrane showed the highest drug release and Fluoropolymer the least. The optimized IVRT method could establish the differences in the drug release rates among the formulations with the altered compositions. The method could also prove its discriminatory potential for various marketed formulations. The immersion cell method could serve as a simple, facile, and reliable aid during product development and also as a quality control tool in assessing stability, aging, and batch-to-batch uniformity of semisolid formulations.

**Keywords:** Immersion cell, acyclovir, in vitro release testing, vertical diffusion cells, nitrocellulose membrane, enhancer cells.

A number of apparatuses, including vertical diffusion cells (VDC), immersion cells, inverted immersion cells, flow-through cells, paddle over disk apparatus, and rotating cylinders apparatus, have been recommended for the IVRT of topical semisolid and transdermal formulations.<sup>1-3</sup> The IVRT has been made mandatory by the U.S. FDA since 2013 as one of the quality and performance parameters for the testing of semisolid formulations. As per the guidance of the U.S. FDA, the IVRT should be performed in a manner described in USP General chapters <734> Semisolid Drug Products.<sup>4</sup> The USP indicates the use of one of the three types of cells—VDCs, commonly known as Franz diffusion cells; immersion cells, also known as Enhancer cells; and Flow-through cells or USP Type 4 apparatus. Of these, VDCs are explored the most for developing and validating IVRT of formulations of many drugs; whereas flow-through cells have been explored the least for this purpose. The immersion cell method employs the routine USP Type 2 dissolution apparatus and needs only a set of 2-l-bottom flasks of 200 ml capacity and mini paddles to conduct the IVRT. Uniform and accurate loading of the semisolid formulation in the immersion cells is easily possible.

DOI: 10.5455/2022.000

© SAGE INDIA PVT. LTD. • VOL. 23, NO. 02 • 2022 ISSN: 0974-7462

*Nyel*  
PRINCIPAL

Indira College of Pharmacy  
Tathawade, Pune - 411033.



SCES'S Indira College of Pharmacy, Pune

Training Program

Criterion - III | SSR | 2022



**CERTIFICATE OF PARTICIPATION**

This is to certify that

**GAIKWAD DHANRAJ**

of Indira College of Pharmacy, Pune  
has successfully participated  
in the Training Program entitled  
"Principle and Applications of USP Dissolution Apparatus 3-7"  
organized by ELECTROLAB India Pvt. Ltd.  
Mahape, Navi Mumbai.

Date: October 5-6, 2017

*Neelam*  
Dr. Neelam Sayed  
Training In-Charge

*Shivani*  
Mrs. Shivani Kamble  
Manager - R & D

*Aditya*  
Mr. Aditya Marfatia  
Director

**CERTIFICATE OF PARTICIPATION**

This is to certify that

**BANKHELE ANKITA**

of Indira College of Pharmacy, Pune  
has successfully participated  
in the Training Program entitled  
"Principle and Applications of USP Dissolution Apparatus 3-7"  
organized by ELECTROLAB India Pvt. Ltd.  
Mahape, Navi Mumbai.

Date: October 5-6, 2017

*Neelam*  
Dr. Neelam Sayed  
Training In-Charge

*Shivani*  
Mrs. Shivani Kamble  
Manager - R & D

*Aditya*  
Mr. Aditya Marfatia  
Director

Principal  
Indira College of Pharmacy  
Tathawade, Pune - 411033.



SCES'S Indira College of Pharmacy, Pune







Training Program

Criterion - III

SSR

2022



PRINCIPAL  
Indira College of Pharmacy  
Tathawade, Pune - 411033.

SCES'S Indira College of Pharmacy, Pune

## Poster Presentation

Criterion -III– Research, Innovations &amp; Extension

SSR

2022



## Poster Presentation

P 046

## IVRT OF ACYCLOVIR SEMISOLID FORMULATIONS USING IMMERSION CELLS: STUDY OF EFFECT OF TEST AND FORMULATION VARIABLES

Kulkarni M., Potdar S., Syed N., Marlatiya A.

Niramay, S No 89/2A, SCES Indira college of Pharmacy, New Pune Mumbai Highway, Tathawade, Pune, Maharashtra-411033, India  
Email: [madhur.kulkarni@indiraicp.edu.in](mailto:madhur.kulkarni@indiraicp.edu.in)**Keywords:** Acyclovir, Immersion Cells, IVRT, semisolids**Aim:** The aim of the present work was to study the impact of test and formulation variables on in vitro release of acyclovir from its semisolid formulations employing Immersion Cells**Objectives-** 1. Study of variables like membrane, stirring rate, media volume, temperature, and size of Immersion cells on in vitro release of acyclovir from the innovator cream formulation. 2. Study of impact of formulation variables such as solvent concentration, method of preparation, consistency, cosolvent concentration on in vitro release of acyclovir. 3. Comparison of acyclovir release from various marketed formulations using the optimized IVRT method**Methodology:** Immersion Cells™ type A were used for optimizing IVRT method of acyclovir topical formulations. The USP Apparatus Type 2 (Electrolab EDT 081x) equipped with flat bottom 200 ml capacity flasks and mini spin paddles was used in the study. Alkaline borate buffer pH 9.2 was chosen as a receptor fluid. Effect of following variables was assessed on the release of acyclovir from its marketed cream formulation (Acicvir®- Cipla). Membrane type - Durapore™/Nitrocellulose/ Fluoropore™. Media volume- 150 mL/200 mL, Media temperature - 32° C/ 37° C. Paddle speed - 50/100/150 RPM, Immersion cell size- 0.5/2/4 cm<sup>2</sup>. Different formulations prepared with changes in the compositions were F1 with same formula as marketed one (Acicvir-Cipla), F2 with the same formula but without the homogenization step, F3 without the use of solvent (Propylene glycol), F4- with higher solvent conc., F5-with altered composition of oil phase, F6 & F7- with polyethylene glycol 200 & 4000 respectively as solvents instead of propylene glycol. All the formulations were subjected to IVRT using Nitrocellulose membrane, 200 mL of the borate buffer maintained at 32° C and agitated at the rpm of 150. The cream was loaded in the immersion cell of 2 cm<sup>2</sup> and the study was performed for 6 h duration with withdrawal of 5 mL aliquots at 0.25, 0.5, 1, 2, 4 and 6 h intervals. Equal volume of the fresh receptor fluid was replaced at every sampling interval. The in vitro drug release rate was computed. Various marketed formulations of acyclovir were subjected to the IVRT using the method mentioned above. The release rates were compared statistically by one-way ANOVA at p ≤ 0.05 using Graphpad prism software (version)**Results:** Nitrocellulose membrane showed greater release of the drug compared to Durapore and Fluoropore. With the increase in the agitation speed from 50 to 100 to 150, the amount of acyclovir release increased linearly. Temperature of the receptor fluid had a significant impact on the release of the drug with higher temperature showing greater release. Media volume of 150 mL showed greater release per mL as compared to 200 mL owing to lesser dilution. As the cell size increased, the drug release also increased proportionately. The media volume of 200 mL at 32°C with 150 rpm paddle speed and cell size of 2 cm<sup>2</sup> employing Nitrocellulose membrane was considered as the optimum method for further studies.

The method was found to be discriminatory with the formulation F4 containing higher solvent concentration showing better release. Absence of propylene glycol in the formulation F3, F6 and F7 reduced the drug release which could be attributed to reduction in the solubility of the drug in the vehicle affecting its diffusion. Drug release from formulation F1 found to be similar to that of the marketed product. Formulation F5 with altered viscosity did show the difference in the release pattern. Finally, the comparison of drug release from various marketed cream formulations showed similar



*Nyel*  
 PRINCIPAL  
 Indira College of Pharmacy  
 Tathawade, Pune - 411 033

SCES'S Indira College of Pharmacy, Pune

[Back to Index](#)

MOU

Abbott Healthcare Pvt Ltd



**1. Confidential Information.** Subject to the limitations set forth in Section 2, all information disclosed by one party ("disclosing party") to the other party ("receiving party") shall be deemed to be "Confidential Information", including, without limitation, this Agreement and the Purpose of this Agreement, any trade secret, information, process, technique, algorithm, computer program (source and object code), design, drawing, formula or test data relating to any research project, work in progress, future development, engineering, manufacturing, marketing, servicing, financing or personnel matter relating to the disclosing party, its present or future products or business, sales, subscribers, suppliers, clients, customers, employees, investors or business, supplied in written, graphic or electronic form and marked or conveyed to receiving party as confidential, and which disclosing party has authority to disclose.

**2. Exclusions.** The term "Confidential Information" does not include information which: (a) is now, or hereafter becomes, through no act or failure to act on the part of the receiving party, generally known or available in the public domain; (b) is independently known by the receiving party at the time of receiving such information as evidenced by its written and dated records; (c) is hereafter obtained by the receiving party from a third party who was legally entitled to possess and disclose such Confidential Information; (d) can be proven to have been independently developed by the receiving party, as evidenced by contemporaneous written and dated records, without using any of the disclosing party's Confidential Information or breaching this Agreement; (e) is the subject of written permission to disclose provided by the disclosing party; (f) is furnished to a third party(ies) by the disclosing party without restrictions, similar to those herein, on the rights of such other third party(ies) or (g) disclosing party is not authorized in law or equity to disclose to receiving party.

**3. Restrictions/Obligations.** Each party agrees that during the Term (as defined in Section 6) of this Agreement it will: (i) only disclose Confidential Information to those employees and contractors with a need to know, provided, the receiving party binds such employees and contractors to terms at least as restrictive as those stated in this Agreement; (ii) not disclose any Confidential Information to any third party, without the prior written consent of the disclosing party; (iii) use Confidential Information only to the extent required to accomplish the Purpose; (iv) not reproduce Confidential Information in any form except as required to accomplish the Purpose; (v) not publish, reverse engineer, decompile, or disassemble any Confidential Information disclosed by the other party; and (vi) promptly provide the other party with notice of any actual or threatened breach of the terms of this Agreement. However, each party may disclose Confidential Information in accordance with a judicial or other governmental order provided that such party shall give the other party reasonable prior written notice prior to such disclosure so that the other party may seek a protective order or other appropriate remedy; in the event that no such protective order or other remedy is obtained, or the other party waives compliance with the terms of this Agreement, such party will furnish only that portion of Confidential Information which it is advised by counsel is legally required and will exercise all reasonable efforts to obtain reliable assurance that confidential treatment will be accorded such Confidential Information.

**4. Ownership.** All Confidential Information (including copies thereof) shall remain the property of the disclosing party and shall be returned upon written request of disclosing party, during the validity of this Agreement or upon completion or termination of this Agreement, provided that receiving party may retain one copy for archival purposes. No rights or licenses to trademarks, inventions, copyrights, patents or trade secrets or other intellectual property rights are implied or granted under this Agreement. Neither party shall use for its own benefit or the benefit of any third party any information disclosed from access to or work with the other party's Confidential Information including, but not limited to, ideas, concepts, know-how or techniques.

**5. Disclaimer.** Confidential Information is delivered "as is", and all representations and warranties, express or implied, including fitness for a particular purpose, merchantability, are hereby disclaimed. No party is entitled to rely on the accuracy or completeness of any Confidential Information. Nothing hereunder shall commit or obligate or be legally binding on either Party to agree to any potential business relationship or to enter into any further agreement or negotiations with the

2 | Page

other or to refrain from entering into an agreement or negotiations with any third parties.

**6. Term.** This Agreement shall be valid for a period of two (2) years from the Effective Date hereof. This Agreement may be terminated by either party at any time upon thirty (30) days written notice to the other party. The termination of this Agreement shall not relieve either party of its obligations with respect to Confidential Information disclosed under this Agreement for a period of three (03) years after the date such Confidential Information is first disclosed.

**7. Equitable Remedies.** The parties acknowledge that monetary damages may not be a sufficient remedy for unauthorized use or disclosure of Confidential Information and that each party shall be entitled, without waiving any other rights or remedies, to seek such injunctive or equitable relief as may be deemed proper by a court of competent jurisdiction.

**8. Publicity.** Neither party may disclose or make any public announcements about the existence or performance of this Agreement, the discussions between the parties or any other matter relating to the Purpose, whether in the form of press release or otherwise, without the other party's prior written consent; provided that the receiving party may share, or disclose about the existence of, this Agreement with its affiliates.

**8. Miscellaneous.** This Agreement constitutes the entire agreement between the parties and shall be governed by, and construed in accordance with the laws of India, subject to exclusive jurisdiction of the courts of Mumbai. Any addition or modification to the Agreement must be in writing and signed by both parties. References to a party under this Agreement shall include the majority owned or controlled entities of such party. Neither party has the right to transfer or assign its interests in this Agreement in whole or in part without the prior written consent of the other party. The failure of a party at any time to insist on performance of any provision of this Agreement is not a waiver of its right at any later time to insist on performance of that or any other provision of this Agreement.

**AGREED TO BY:**

<b>ABBOTT HEALTHCARE PRIVATE LIMITED</b> (Healthcare Solutions Division)	<b>SCES'S INDIRA COLLEGE OF PHARMACY</b>
Sign: <u>[Signature]</u>	Sign: <u>[Signature]</u>
[Name] <u>Dr. Kavi Raj Pillai</u>	[Name] <u>Dr. Aragha Joshi</u>
[Title] <u>Sr. Director and Head, I &amp; D, ERD</u>	[Title] <u>Principal</u>
[Date] <u>12<sup>th</sup> Nov 2013</u>	[Date] <u>14<sup>th</sup> March 2013</u>

3 | Page

## SUMMARY



Shree Chanakya Education Society's

## Indira College of Pharmacy, Pune

"Redefining Pharmacy Education"

**NAAC: B++**

Approved by PCI, AICTE, New Delhi, Affiliated to SPPU & MSBTE, Recognized by Govt. of Maharashtra

### SUMMARY

The company is interested in manufacturing and marketing the novel dental product developed by one of the faculty members, Dr. Madhur Kulkarni and her research group. Considering the interest of the company in translating the product to commercial scale, Dr. Madhur along with Ms. Meghna Dabhadkar has filed a product patent in March 2018. The patent specification is currently under examination. Once the patent is granted, further collaborative activity with the company will be continued.



Dr. Anagha M Joshi

**PRINCIPAL**

Indira College of Pharmacy  
Tathawade, Pune - 411 033

**Patent Information**



Shree Chanakya Education Society's  
**Indira College of Pharmacy, Pune**  
 "Redefining Pharmacy Education"

NAAC : B++

Approved by PCI, AICTE, New Delhi, Affiliated to SPPU & MSBTE, Recognized by Govt. of Maharashtra

(12) PATENT APPLICATION PUBLICATION	(21) Application No.201821012037 A
(19) INDIA	
(22) Date of filing of Application :29/03/2018	(43) Publication Date : 24/07/2020
(54) Title of the invention : A NOVEL THERMOREVERSIBLE COMPOSITION	
(51) International classification	:A61K0009000000, (71)Name of Applicant : A61K0047100000, 1)Mrs. Madhur C. Kulkarni A61K0008190000, Address of Applicant :1-203, Samranya CHS, Shivteerth Nagar, A61Q0011000000, Kothrud, Pune 411038, Maharashtra India A61K0006000000 (72)Name of Inventor : 1)Mrs. Madhur C. Kulkarni 2)Meghna Mansur Dabhadkar
(31) Priority Document No	:NA
(32) Priority Date	:NA
(33) Name of priority country	:NA
(86) International Application No	:NA
Filing Date	:NA
(87) International Publication No	:NA
(61) Patent of Addition to Application Number	:NA
Filing Date	:NA
(62) Divisional to Application Number	:NA
Filing Date	:NA

(57) Abstract  
 Abstract Present invention relates to a novel thermoreversible composition for treating dentin hypersensitivity comprising at least one desensitizing agent selected from the group consisting of potassium nitrate, sodium fluoride, potassium oxalate, strontium fluoride, calcium carbonate, calcium phosphate and zinc chloride. The composition comprises of at least one grade of thermoreversible polymer selected from the group consisting of poloxamer 188, poloxamer 407, poloxamines 994, poloxamines 1107 and poloxamines 1307. Preferably poloxamer 407 solubilized in at least one vehicle selected from the group consisting of water, ethanol, and propylene glycol. At least one preservative selected from the group consisting of methyl paraben, propyl paraben, sodium benzoate and lactic acid at a percentage ranging from 0.01 to 0.5% is present in the composition. The composition is characterized in that ratio of said drug to thermoreversible polymer ranges between 1:3 and 1:15; ratio of said desensitizing agent to vehicle ranges from 1: 15 to 1: 50 and ratio of said preservative to vehicle ranges between 1:200 and 1: 10,000. The viscosity of said thermoreversible formulation ranges from 100 to 400 cps in the temperature range of 25-8 °C.

No. of Pages : 22 No. of Claims : 10



**PRINCIPAL**  
 Indira College of Pharmacy  
 Fathawade, Pune - 411 033




The Patent Office Journal No. 30/2020 Dated 24/07/2020

27850

[Back to index](#)

**MOU**

**McW Healthcare**





Date: 03/12/2019

**Memorandum of Understanding between MeW Healthcare Pvt.Ltd and SCES's, Indira College of Pharmacy, Pune**

MeW Healthcare [P] Ltd. and SCES' Indira College of Pharmacy (ICP) hereby agree to enter into a Memorandum of Understanding (MoU) for academic and professional collaboration with the purpose of mutual benefit. MeW Healthcare [P] Ltd has been in pharmaceutical business for past 3 decades with over 400 products in various therapeutic segments covering wide spectrum of diseases from communicable, non-communicable or even rare diseases. ICP was established in 2006 and since then offers the courses of B.Pharmacy, M.Pharmacy and Doctor of Pharmacy. Both parties agree that giving exposure to the students to cutting edge technologies and practical projects will enable students to secure jobs as well as pursue entrepreneurship options. Both parties agree to the following terms

**Industrial & Corporate Relations:**

- a. Both organizations will work closely to come up with models of regular engagement between ICP students and Faculties and MeW Healthcare trainers, developers and project managers.
- b. MeW Healthcare will allow ICP undergraduates and post-graduates and Faculty to visit their lab and attend technology conferences and events that MeW Healthcare organizes for exposure and practical knowledge.
- c. Looking at the expansion plan of MeW Healthcare large pool of skilled manpower at different levels for small projects or for final hiring purpose will be required in the coming years. MeW Healthcare will offer training to the students of ICP with/without a stipend in the form of internship and as per their performance may offer placement.

**Research:**

- a. MeW Healthcare and ICP will work together on joint research projects in areas of mutual interest. The projects designed or conceptualized by ICP faculty/ students will be executed partly at MeW Healthcare and partly in the college after approval of the research proposal by MeW Healthcare. Vice versa will also be possible.
- b. The research work undertaken jointly by ICP and MeW Healthcare will be published in reputed journals under the ownership of both the parties. In case of patentable research, both the parties would be the applicants of IPR and will share the benefits on equal basis.
- c. Library and Lab facilities will be provided by ICP as and when required to MeW Healthcare employees on a prior notice for the research work. For the use of sophisticated instruments and equipment, no charges will be applicable.



d. McW Healthcare will allow the students and faculty of ICP to use sophisticated instruments and equipment on a prior notice for the research work. This kind help extended by McW Healthcare will be duly acknowledged by the students and faculty in their research publications and dissertation.

e. McW Healthcare may donate some equipments and parts of manufacturing/analytical apparatus to ICP for research purpose.

**f. Consultancy:**


ICP believes in inviting and involving Corporate Professionals for Board of Advisors, Guest Lectures, Workshops, Seminars and similar events for which expert/s are required for enhancing knowledge, skills and attitude of Faculty & Students. To achieve this objective, whenever possible, McW Healthcare will allow their professionals to visit ICP. ICP will also allow their faculty to visit McW Healthcare for sharing their knowledge and expertise in the area of interest for McW Healthcare.

**Contact Persons**

Ms. Roopal Bhat will be the contact person for ICP to initiate, manage or execute any joint activities between ICP and Mr. Abhijeet Motiwale will be the contact person for McW Healthcare.

  
Name: Mr. Abhijeet Motiwale

By: Director- McW Healthcare [P] Ltd

  
Name: Dr. (Mrs.) Anagha Joshi

By: Principal - ICP

Date: 3/12/2019

#### NON-DISCLOSURE AGREEMENT

THIS NON-DISCLOSURE AGREEMENT (this "Agreement") is made and entered into as of between McW Healthcare, Pune and Indira College of Pharmacy(ICP), having its education setup at Niramay, S.No 89/2A, New Pune Mumbai Highway, Tathwade, Pune, Maharashtra – 411033. **Purpose:** McW Healthcare and ICP wish to explore Opportunities in Training, Corporate Relations, Research, & consultancy of mutual interest and in connection with this opportunity wishes to execute this Non-Disclosure Agreement ("NDA").

**1. Confidential Information:** Confidential information means any information disclosed to by one party to the other, either directly or indirectly in writing, orally or by inspection of tangible or intangible objects, including without limitation documents, business plans, source code, software, hardware, application and uses of hardware and software, documentation, financial analysis, marketing plans, customer names, customer list, customer data. Confidential Information may also include information disclosed to a party by third parties at the direction of a Disclosing Party. Confidential Information shall not, however, include any information which the Receiving party can establish (i) was publicly known and made generally available in the public domain prior to the time of disclosure; (ii) becomes publicly known and made generally available after disclosure through no action or inaction of Receiving Party; or (iii) is in the possession of Receiving Party, without confidentiality restrictions, at the time of disclosure by the Disclosing Party as shown by Receiving Party's files and records immediately prior to the time of disclosure. The party disclosing the Confidential Information shall be referred to as "Disclosing Party" in the Agreement and the party receiving the Confidential Information shall be referred to as "Receiving Party" in the Agreement.

**2. Non-use and Non-disclosure:** The Receiving Party agrees not to use any Confidential Information for any purpose except to evaluate and engage in discussions concerning a potential business relationship between the parties hereto. Receiving Party agrees not to disclose any Confidential Information to third parties or to its employees, except to those employees who are required to have the information in order to evaluate or engage in discussions concerning the contemplated business relationship. The Receiving Party shall not reverse engineer, disassemble or decompile any prototypes, software or other tangible objects which embody the Disclosing Party's Confidential Information and which are provided to the Receiving Party hereunder.

**3. Maintenance of Confidentiality Information:** The Receiving Party agrees that it shall take all reasonable measures to protect the secrecy of and avoid disclosure and unauthorized use of the Confidential Information. Without limiting the foregoing, Receiving Party shall take at least those measures that Receiving Party takes to protect its own most highly confidential information and shall have its employees, if any, who have access

to Confidential Information sign a non-use and non-disclosure agreement in content substantially similar to the provisions hereof, prior to any disclosure of Confidential Information to such employees. The Receiving Party shall not make any copies of Confidential Information unless the same are previously approved in writing by the Disclosing Party. The Receiving Party shall reproduce the Disclosing Party's proprietary rights notices on any such approved copies, in the same manner in which such notices were set forth in or on the original. The Receiving Party shall immediately notify the Disclosing Party in the event of any unauthorized use or disclosure of the Confidential Information.

4. **No Obligation:** Nothing herein shall obligate either party to preceed with any transaction between them, and each party reserve the right, in its sole discretion, to terminate the discussions contemplated by this Agreement concerning the business opportunity.

5. **No Warranty:** ALL CONFIDENTIAL INFORMATION IS PROVIDED "AS IS". NEITHER PARTY MAKES ANY WARRANTIES, EXPRESS, IMPLIED OR OTHERWISE, REGARDING ITS ACCURACY, COMPLETENESS OR PERFORMANCE.

6. **Return of Materials:** All documents and other tangible objects containing or representing Confidential Information and all copies thereof which are in the possession of Receiving Party shall be and remain the property of the Disclosing Party and shall be promptly returned to the Disclosing Party upon the Disclosing Party's request.

7. **No License:** Nothing in this Agreement is intended to grant any rights to either party under any patent, mask work right or copyright of Company, nor shall this Agreement grant Receiving Party any rights in or to Confidential Information except as expressly set forth herein.

8. **Term:** This Agreement shall survive for a period of 1 year (renewable and extended up to 3 years) from the date of disclosure of the Confidential Information.

9. **Remedies:** The Receiving Party agrees that any violation or threatened violation of this Agreement will cause irreparable injury to the Disclosing Party, entitling the Disclosing Party to obtain injunctive relief in addition to all legal remedies.

10. **Miscellaneous:** This Agreement shall bind and inure to the benefit of the parties hereto and their successors and assigns. This document contains the entire agreement between the parties with respect to the subject matter hereof. Any failure to enforce any provision of this Agreement shall not constitute a waiver thereof or of any other provision hereof. This Agreement may not be amended, nor any obligation waived, except by a writing signed by both parties hereto. The parties have executed this Nondisclosure Agreement as of the date first above written.

[McW Healthcare]

[ICP]



By: Director

Name: Mr. Abhijeet Motiwale



By: Principal

Name: Dr. Anagha Joshi

Date: 3/12/2019



**SUMMARY**

Shree Chanakya Education Society's

**Indira College of Pharmacy, Pune**

"Redefining Pharmacy Education"

**NAAC: B++**

Approved by PCI, AICTE, New Delhi, Affiliated to SPPU &amp; MSBTE, Recognized by Govt. of Maharashtra

**SUMMARY**

Title: Activities Carried out under MOU (McW)		
S.No	Topic	Class
1	Guest Lecture	B.Pharm Final Year



*Mjeh*  
Dr. Anagha M Joshi  
PRINCIPAL  
Indira College of Pharmacy  
Tathawade, Pune - 411 033

## Guest Lecture

**Shree Chanakya Education Society's  
INDIRA COLLEGE OF PHARMACY, PUNE**

(Approved by Pharmacy Council of India, All India Council for Technical Education, New Delhi, Directorate of Technical Education (MS) and Government of Maharashtra- Affiliated to Savitribai Phule Pune University, Accredited by NAAC B++ Grade)  
ID No. PU/PN/Pharmacy/258/2006 AISHE Code- C-41396

Ref No. SCES/ ICP/ 2019-2020/

Date: 22<sup>th</sup> April, 2020

To,  
Mr Abhijeet Motiwale  
Director, McW Healthcare,  
Indore.

Sub: Sessions on “Entrepreneurship Development Webinar Series”

Dear Sir,

Indira College of Pharmacy was established under the auspices of Shree Chanakya Education Society. It is one of the most reputed Educational organizations which has created its own forte in the educational arena around Pune in a very small span and is branded as a premier educational institution.

We reckon that you are one of the few self-motivated, dedicated and experienced professionals, nurturing professional & ethical values and boosting the noble profession of Health Sciences in the country.

We are privileged to invite you at **Indira College of Pharmacy, Tathawade, Pune – 411033** for delivering Online session. We request you to conduct webinar series sessions on “**Entrepreneurship Development**” at our institute on 30<sup>th</sup> April 2020.

We would be honored if you kindly accept our invitation and spare your valuable time to guide our students.

Thanking you,

Yours faithfully,

  
(Dr. Anagha Joshi)

**PRINCIPAL**  
**Indira College of Pharmacy**  
**Tathawade, Pune - 411 033**



Address : Niramay, 89/2 A, New Pune Mumbai Highway, Tathawade, Pune- 411033 India  
Tel No. 020- 66759601/ 603/604 Fax: 020-66759601  
Email- [adminicp@indiraicp.edu.in](mailto:adminicp@indiraicp.edu.in) Website : [www.indiraicp.edu.in](http://www.indiraicp.edu.in)

## Guest Lecture



## Shree Chanakya Education Society's

## INDIRA COLLEGE OF PHARMACY, PUNE

(Approved by Pharmacy Council of India, All India Council for Technical Education, New Delhi, Directorate of Technical Education (MS) and Government of Maharashtra- Affiliated to Savitribai Phule Pune University, Accredited by NAAC B++ Grade)  
ID No. PU/PN/Pharmacy/258/2006 AISHE Code- C-41396

Ref No. SCES/ ICP/ 2019-2020/

Date: 30<sup>th</sup> April, 2020

To,  
Mr Abhijeet Motiwale  
Director, McW Healthcare,  
Indore.

Sub: Sessions on "Entrepreneurship Development Webinar Series"

Dear Sir,

We would like to express our sincere thanks to you. It was a unique opportunity for all the students to have an interaction with you. We are extremely thankful to you for sparing your valuable time and delivering such an excellent session to our students on "Entrepreneurship Development Webinar Series".

We positively look forward for a long term association with you and for your valuable guidance in mentoring our students.

Thanking you,

Yours faithfully,



(Dr. Anagha Joshi)



Principal  
Indira College of Pharmacy  
Tathawade, Pune - 411 033


Address : Niramay, 89/2 A, New Pune Mumbai Highway, Tathawade, Pune- 411033 India  
Tel No. 020- 66759601/ 603/604 Fax: 020-66759601  
Email- [adminicp@indiraicp.edu.in](mailto:adminicp@indiraicp.edu.in) Website : [www.indiraicp.edu.in](http://www.indiraicp.edu.in)



Guest Lecture



*Shree Chanakya Education Society's*  
**INDIRA COLLEGE OF PHARMACY, PUNE**  
*"Redefining Pharmacy Education"*



*Myel*  
**PRINCIPAL**  
Indira College of Pharmacy  
Tathawade, Pune - 411 033

[Back to Index](#)

**MOU**

**Mprex Healthcare Pvt Ltd**

**MEMORANDUM OF UNDERSTANDING**

**BETWEEN**

**SCES's Indira College of Pharmacy, Pune**

**AND**

**M/S. Mprex Healthcare Pvt. Ltd.,**

**UNIT NO. 501, CROSSROAD BUILDING, BHUMKAR SQ,**

**WAKAD, PUNE 4115057**

**ON**

**COLLABORATION IN**

**EXCHANGE OF RESEARCH AND**

**EXPERTISE**

**MEMORANDUM OF UNDERSTANDING  
BETWEEN  
SCES's INDIRA COLLEGE OF PHARMACY, PUNE  
AND  
M/S. MPREX HEALTHCARE PVT. LTD.,  
UNIT NO. 501, CROSSROAD BUILDING, BHUMKAR SQ, WAKAD, PUNE 4115057  
ON  
COLLABORATION IN EXCHANGE OF RESEARCH AND EXPERTISE**

Whereas,

The SCES's Indira College of Pharmacy, Pune (contract acceptor) and M/S Mprex Healthcare Pvt. Ltd. (contract giver) signed a Memorandum of Understanding on Collaboration in exchange of research and expertise on 01<sup>st</sup> June, 2020;

The Participants have reached the following understanding:

**SECTION 1**

**Objective**

The objective of the collaboration under this Memorandum of Understanding (MOU) will be to continue, expand, and maximize cooperation in research and development between the Participants. Collaboration under this MOU will not preclude other bilateral or multilateral cooperation activities in exchange of research and expertise in which each Participant may take part.

**SECTION 2**

**Scope**

1. Collaboration under this MOU may include, but is not limited to, the following fields:
  - a. Herbal Product development
  - b. Standardization of the pharmaceutical raw materials and / or products
  - c. Analytical method development
  - d. Analytical support in some cases as the need arises.
2. Other collaborative fields may be added by written arrangement of the Participants.

#### Forms of Collaborative Activities

1. Collaboration in accordance with this MOU may include, but is not limited to, the following forms:
  - a. Exchange of all forms of unclassified scientific and technical information and results of research and development for the projects mutually agreed to do;
  - b. Exchange of scientists, other specialists, including those from industry, for participation in research, development, analysis, design and experimental activities conducted in research centers, laboratories, and other facilities and enterprises of each Participant;
  - c. Exchange of samples, materials, instruments and components for testing for the projects mutually agreed to do;
  - d. Organization of seminars, workshops, and other meetings on specific topics;
  - e. Visits by specialist teams or individuals to the facilities of the other Participant;
  - f. The use by one Participant of the facility (ies) owned or operated by the other Participant. Such use of facilities will be the subject of a separate written arrangement and may be subject to commercial terms or conditions;
  - g. Cooperative programs and projects in which the Participants decide to share the work and costs. Such joint projects will be the subject of a separate written arrangement between the Participants.
  - h. The collaborative projects and assignments may be given for the ICP students.
  - i. Mprex will offer opportunity for placement to ICP students wherever applicable.
2. Other specific forms of cooperation may be added by written agreement of the Participants.

#### SECTION 4

##### Other Entities

1. The Participants will encourage and facilitate, where appropriate, the development under this MOU of direct contacts and cooperation between universities, science and research centers, institutes and institutions, private sector firms.
2. To supervise the cooperation under this MOU, each Participant will designate a Lead Coordinator. Each Participant will also designate a Technical Coordinator to assist the Lead Coordinator in carrying out activities under this MOU.

The Lead Coordinators will evaluate the status of cooperation under this MOU. This evaluation will include a review of the past year's activities and accomplishments and of the activities planned for the coming year within each of the fields listed in Section 2,

**SECTION 5**

## Intellectual Property; Business-Confidential Information

The Participants do not anticipate the generation of intellectual property from the activities under this MOU or the exchange of business-confidential information. If the Participants determine that a particular activity may lead to the creation of intellectual property or the exchange of business confidential information, they will consult with each other and make appropriate written arrangements for the protection and allocation of such intellectual property and business confidential information.

**SECTION 6**

## Funding

1. Collaboration under this MOU will be subject to the availability of appropriated funds.
2. SCES's Indira College of Pharmacy, Pune, will raise requirement of chemicals and other materials for proposed work agreed between the two participants. Mprex Healthcare Pvt. Ltd. would supply those chemicals or materials.
3. In case SCES's Indira College of Pharmacy, Pune has to make arrangements to buy the chemicals or materials Mprex Healthcare Pvt. Ltd. would authorize to do so. Payment for the procurement of chemicals or other materials will be done by Mprex Healthcare Pvt. Ltd.
4. In addition to the above mentioned expenses SCES's Indira College of Pharmacy, Pune & Mprex Healthcare Pvt. Ltd. will agree upon the fix amount as consultation charges towards the work assigned to SCES's Indira College of Pharmacy, Pune. At the time of collaborative work assignment confirmation SCES's Indira College of Pharmacy, Pune will raise the invoice for the work and will submit to Mprex Healthcare Pvt. Ltd. along with the report of the work completed. Mprex Healthcare Pvt. Ltd. will pay the amount to SCES's Indira College of Pharmacy, Pune

**SECTION 7**


## Equipment

The participants will provide the necessary premises and allow use of equipment for carrying out mutually agreed upon research work activities.

**SECTION 8**

## Samples and Materials

1. Unless otherwise agreed in writing, the following provisions will apply to the transportation and use of samples and materials provided by one Participant to the other under this MOU:
2. Unless otherwise agreed by the Participants, all samples and materials provided by the sending Participant to the receiving Participant will remain the property of the sending Participant, and will be returned to the sending Participant upon completion of the mutually agreed activity.
3. Where one Participant requests that a sample or material be provided by the other Participant, the Participant providing the sample or material will bear all costs and expenses associated with the transportation of the sample or material from the location of the sending.
4. Subject to the provisions of Section 5, each Participant will promptly disclose to the other Participant all information arising before and after the examination or testing of samples or materials exchanged under this MOU.



## SUMMARY



*Shree Chanakya Education Society's*  
**Indira College of Pharmacy, Pune**  
*"Redefining Pharmacy Education"*


**NAAC: B++**

Approved by PCI, AICTE, New Delhi, Affiliated to SPPU & MSBTE, Recognized by Govt. of Maharashtra

### SUMMARY

Title: Activities carried out under MOU (Mprex Healthcare Ltd)					
S.No.	Name of the Activity	Year	Name of the students	No of the students	Class
1	Certification Course in Clinical Research	2019-2020	Akash Shete Ms. Dhruvi Gosar Ms. Himani Damania Ms. Simran Shah Mr. Abdolrab Malekraeisi Mr. Atoofa Akbar Bade Mr. Dylan Fernandes Ibrahim Khaled Ali Jayant Pravin Pawar Murtaza Neemuchwala Mustafa Khaled Ali Suhad Khaled Ali Yussif Faissl Alshuka Akanksha Govind Jadhav Anisha Thomas Ankita Tukaram Veer Arohi Deshmukh Damini Kolhe Mausmi Shah Muna Khaled Ali Naisha Verlekar Nargis Patel Reshma Mathew Savya Jayachandran Shambhavi Ranade Shruti Anant Kalambate	28	Final Year B. Pharm

  
**PRINCIPAL**  
**Indira College of Pharmacy**  
**Tathawade, Pune - 411 033**





*Shree Chanakya Education Society's*  
**Indira College of Pharmacy, Pune**

*"Redefining Pharmacy Education"*

**NAAC: B++**

Approved by PCI, AICTE, New Delhi, Affiliated to SPPU & MSBTE, Recognized by Govt. of Maharashtra

			Snehal Narayan Todkar Vinitha Nadar		
2.	Certification Course in Pharmaceutical Drug Regulatory Affairs	2021-2022	Atharva Shivade Rushikesh Lad Anuradha Kite Abhishek Bodkhe Pradnya Londhe Aashutosh Yeole Vedika Deshmukh Vaishnavi Ghodekar Gargi Deshmukh Aarti Kharade Amey Goregaonkar Shomita Shetty	12	Final Year B. Pharm
3	Placement	2020-2021	Agraja Bhise Nikita Joshi	2	Final Year B. Pharm
4	Internship	2021-2022	Varad Shisode Yogesh Pawar	2	M. Pharm



Dr. Anagha M Joshi

**PRINCIPAL**  
 Indira College of Pharmacy  
 Tathawade, Pune - 411 033





Certification Course in Clinical Research


Criterion - III – Research, Innovations & Extension

SSR

2022




Certification Course in Clinical Research



ONLINE CERTIFICATE PROGRAM

# CLINICAL RESEARCH

Offered by



Mprex Healthcare Pvt. Ltd.

**STARTS**  
**DECEMBER 12, 2020**  
**3 MONTH COURSE**  
**EVERY SAT & SUN**  
**FEES 8000/-**



*myeh*  
**PRINCIPAL**  
Indira College of Pharmacy  
Tathawade, Pune - 411 033

SCES'S Indira College of Pharmacy, Pune

Certification Course in Clinical Research

Criterion - III – Research, Innovations & Extension

SSR

2022



Certification Course in Clinical Research



Mprex Healthcare Pvt. Ltd. | S.C.E.S's Indira College of Pharmacy

**CERTIFICATE OF COMPLETION**

This is awarded to

for completing 3 months Course in Clinical Research with grade, Organised by Mprex Healthcare P. Ltd. in collaboration with S.C.E.S's Indira College of Pharmacy

12-04-2021  
Date

*Dayana Ch...*  
Authorized Signatory

ASCP | Australian Clinical Trials Alliance | ACRP MEMBER | FISCR | CERTIFIED ISO COMPANY



*mych*  
**PRINCIPAL**  
Indira College of Pharmacy  
Tathawade, Pune - 411 033

SCES'S Indira College of Pharmacy, Pune

Certification Course in Clinical Research

Criterion - III – Research, Innovations & Extension

SSR

2022



Certification Course in Clinical Research



*Handwritten signature*

**PRINCIPAL**  
**Indira College of Pharmacy**  
**Pathawade, Pune - 411 033**



SCES'S Indira College of Pharmacy, Pune



Certification Course in Clinical Research



Certification Course in Clinical Research



*Handwritten signature*  
PRINCIPAL  
Indira College of Pharmacy  
Pathwade, Pune - 411 033



SCES'S Indira College of Pharmacy, Pune

Certification Course in Pharmaceutical Drug Regulatory Affairs


Criterion - III – Research, Innovations & Extension

SSR

2022



Certification Course in Pharmaceutical Drug Regulatory Affairs



**CERTIFICATE COURSE IN PHARMACEUTICAL DRUG REGULATORY AFFAIRS 2021-2022**  
Designed For • Academia • Research Scholars • Faculty

CONDUCTED BY  
**INDIRA COLLEGE OF PHARMACY, PUNE**  
Shree Dhansha Education Society  
"Empowering Minds to Devote Lives"

INDIA'S COLLABORATION WITH  
**GLOBAL SCHOOL OF MANAGEMENT AND RESEARCH**  
Tathawade, Pune - 411 033 INDIA  
A academic venture of Mprex Healthcare P. Ltd.

**COURSE DETAILS**

<b>TOTAL COURSE DURATION</b> <b>45 HOURS</b>	<b>Course Details</b> <ul style="list-style-type: none"><li>Principles of GMP</li><li>Indian Regulatory Systems</li><li>Introduction to DMF and Dossier</li><li>Certificate of Analysis and process/method validation</li><li>ICH Guideline</li><li>International Regulatory Systems - US, EU and ROW</li><li>Regulatory Software Demo, MSOS Writing, SmpPC Writing</li></ul>	<b>Course Highlights</b> <ul style="list-style-type: none"><li>Weekend batches</li><li>Platform to interact with DRA Experts</li><li>Hands on training - DRA Software</li><li>Real Time Industrial case studies</li><li>Course Evaluation</li><li>Certificate of Merit</li></ul>
---	---	--

**CONVENER**  
Dr. Anagha Joshi  
Principal

**COORDINATORS**  
Dr. Manasi Wagdarikar

**REGISTRATION**  
Ms. Nikita Joshi  
+91 8010 3474 52


*Anagha Joshi*  
**PRINCIPAL**  
Indira College of Pharmacy  
Tathawade, Pune - 411 033



SCES'S Indira College of Pharmacy, Pune



Certification Course in Pharmaceutical Drug Regulatory Affairs



Offer Letter


Criterion - III – Research, Innovations & Extension

SSR

2022



Offer Letter



**MPREX HEALTHCARE**  
Crossroad, 501, Bhumkar Sq, Wakad Pune - 411057  
E: info@mprex.in, www.mprex.in

**OFFER LETTER**

06/09/2020

Ms. Agraja Bhise  
Trainee Associate – Business Development and Digital Marketing (BDOM)  
Pune.

Dear Ms. Agraja Bhise

I am pleased to inform you that you have been selected for the role of Trainee Associate – Business Development and Digital Marketing (BDOM). This is an offer letter confirming your training period with Mprex Healthcare starting on 07.09.2020

Your training period is subject to the terms and conditions detailed in the contract document supplied individually with this letter.


As discussed and agreed with you, you will be eligible to receive the following beginning on your joining date:


- Stipend of Rs 8000/- (Eight Thousand)
- Performance bonus 2000/- (Two hundreds)
- Business Travel allowance and reimbursements as per company policy for Outside Pune.

Congratulations on your selection as Trainee Associate – Business Development and Digital Marketing (BDOM) and welcome to Mprex Healthcare. We look forward to years of fruitful cooperation and success. We wish you the best of luck in your new post.

Sincerely,

Authorize Signatory  
Dr. Dheeraj Nagore  
Director - Mprex Healthcare



  
PRINCIPAL  
Indira College of Pharmacy  
Tathawade, Pune - 411 033



SCES'S Indira College of Pharmacy, Pune



Offer Letter


Criterion - III – Research, Innovations & Extension

SSR

2022



Offer Letter

 **MPREX HEALTHCARE**  
 Crossroad, 501, Bhamburda Sq, Wakad Pune - 411057  
 E: info@mprex.in, www.mprex.in

**OFFER LETTER**

03/11/2020

Ms. Nikita Joshi  
 Trainee Associate – Business Development and Digital Marketing (BDDM)  
 Pune.

Dear Ms. Nikita Joshi

I am pleased to inform you that you have been selected for the role of Trainee Associate – Business Development and Digital Marketing (BDDM). This is an offer letter confirming your training period with Mprex Healthcare starting on 03.11.2020.



Your training period is subject to the terms and conditions detailed in the contract document supplied individually with this letter.

As discussed and agreed with you, you will be eligible to receive the following beginning on your joining date:


- Stipend of Rs 8000/- (Eight Thousand)
- Performance bonus 2000/- (Two hundreds)
- Business Travel allowance and reimbursements as per company policy for Outside Pune.


Congratulations on your selection as Trainee Associate – Business Development and Digital Marketing (BDDM) and welcome to Mprex Healthcare. We look forward to years of fruitful cooperation and success. We wish you the best of luck in your new post.

Sincerely,

Authorise Signatory  
 Dr. Dheeraj Nagore  
 Director - Mprex Healthcare



  
**PRINCIPAL**  
 Indira College of Pharmacy  
 Tathawade, Pune - 411 033



SCES'S Indira College of Pharmacy, Pune



### Internship

Criterion - III – Research, Innovations & Extension | SSR | 2022

Internship

**Mprex Healthcare Pvt. Ltd.**


*Letter of Experience*

To, 20 March 2022  
Mr. Varad Tanaji Shisode,

This is to certify that, Mr. Varad Tanaji Shisode, M pharm student of Indira College of Pharmacy, Pune worked as a Project Trainee at Mprex Healthcare Pvt. Ltd. between the Period 15/10/2021 to 15/02/2022.

Mr. Varad Tanaji Shisode successfully Completed his M pharm project work titled "Design and Development of Tools and Software for Processing Detain Clinical Research" during this period and has submitted the project report for our records.


We wish him all the best for his future endeavors.

*Vaishnavi Padar*   
**Miss. Vaishnavi Padar**  
HR Manager  
Mprex Healthcare Pvt.Ltd.

ADDRESS  
501, Crossroad  
Building, Bhumkar  
Square, Wakad,  
Pune-411057

CONTACT  
+91 80103 47452

*Principal*  
PRINCIPAL  
Indira College of Pharmacy  
Tathawade, Pune - 411 033



SCES'S Indira College of Pharmacy, Pune

### Internship


Criterion - III – Research, Innovations & Extension

SSR

2022



### Internship



**Mprex Healthcare Pvt. Ltd.**

*Letter of Experience*

To, 03 June 2022  
Mr. Yogesh Kisan Pawar,

This is to certify that, Mr. Yogesh Kisan Pawar, M. pharm student of Indira College of Pharmacy, Pune worked as a Project Trainee at Mprex Healthcare Pvt. Ltd. between the Period 15/10/2021 to 30/05/2022.

Mr. Yogesh Kisan Pawar successfully Completed his M pharm project work titled "Design and Development of Tools and software for Privacy and security issues during Data Management" during this period and has submitted the project report for our records.

We wish him all the best for his future endeavors.

*Vaishnavi Padar*  
**Miss. Vaishnavi Padar**  
HR Manager  
Mprex Healthcare Pvt.Ltd..

ADDRESS  
501, Crossroad  
Building, Bhumber  
Square, Wakad,  
Pune- 411057

CONTACT  
+91 90103 47452

*nyel*  
PRINCIPAL  
indira College of Pharmacy  
Tathawade, Pune - 411 033





SCES'S Indira College of Pharmacy, Pune

[Back to Index](#)

**MOU**

**Jehangir Centre for Learning**





NOW, THEREFORE, IN CONSIDERATION OF THE MUTUAL COVENANTS AND AGREEMENTS SET FORTH HEREIN AND FOR OTHER GOOD AND VALUABLE CONSIDERATION, THE RECEIPT AND SUFFICIENCY OF WHICH IS HEREBY ACKNOWLEDGED, THE PARTIES HERETO AGREE AS FOLLOWS.

**2. ENGAGEMENT AND SCOPE OF THE AGREEMENT**

2.1 This Agreement is the master agreement between the Parties. JCL hereby collaborates with Indira College of Pharmacy, Tathawade, Pune, a non-exclusive basis for the purpose as mentioned hereinabove in the recitals. However, for the purpose of abundance of clarity, JCL reserves the right to enter into similar arrangements with any other Parties and Academic Partner agree that, Academic Partner shall in no manner whatsoever interfere with the same. Academic Partner further agrees that, Academic Partner shall in no manner whatsoever engage any other third parties for this purpose, without the prior written consent of JCL.

2.2 The main purpose of the Agreement is to foster collaboration between JCL and the Academic Partner, to provide opportunity for global experience to students, and facilitate advancement of knowledge in clinical research and various facets associated with it in terms of well-planned course modules.

2.3 JCL and Academic Partner will extend to each other the facilities and resources available with them through working out the necessary modalities from time to time and case-by-case for smooth conduct of the course.

2.4 JCL would conduct its e-learning courses and Post Graduate Diploma in Clinical Research [Online mode] in collaboration with the Academic Partner. This Memorandum of Agreement is signed by both Parties as per the mutually acceptable terms and conditions.

**JCL'S RESPONSIBILITIES:**

**For e-learning course**

The execution of the course will be JCL's responsibility. JCL would manage the day-to-day operations of the course. The following would be the responsibilities





- Generating the Log-in ID and Password on JCL's E-learning Portal after written confirmation is received from Academic Partner about completion of the admission of the student/s and after receiving the fees into JCL bank account.
- Conducting virtual doubt clearing sessions.
- Additional reading material shall be available on the E-Learning Portal.
- Conducting exams through the E-Learning Portal.

**For Post Graduate Diploma in Clinical Research [Online Mode]**

The execution of the course will be JCL's responsibility. JCL would manage the day-to-day operations of the course. The following would be the responsibilities

- Student Counseling
- Providing lecture schedule to the students on Academic Partner well in advance.
- Management of faculty.
- Conduct of lectures.

Memorandum of Agreement between Jehangir Clinical Development Centre's JCL and Indira College of Pharmacy, Tathawade, Pune.

- Sharing online study material
- conducting test
- Fee collection
- Assistance in placement efforts in association with Academic Partner's placement cell.

**ACADEMIC PARTNER'S RESPONSIBILITIES:**

Academic Partner shall create awareness, market the course and provide logistic and infrastructure support such as-

**For e-learning course**

- Awareness creation, marketing of the course and enrollment of students into the course.
- Communicate and Coordinate with JCL for creation of user ID and Password for the enrolled students.

**For Post Graduate Diploma in Clinical Research (Online Mode)**

- Awareness creation, marketing of the course and enrollment of students into the course.
- Providing computer labs for attending online sessions, if required.
- Support for collection of fees. e.g. periodic reminders.

Both JCL and the Academic Partner will appoint one person as a single point of contact from each side. These individuals will communicate with each other on a regular basis to sort out administrative issues and review progress.

**3. TERM**




3.1 This Agreement shall continue for the period of three years from the date of signing of this Agreement until its termination in accordance with Clause 7. The Parties agree that the Agreement can be renewed by the Parties in writing mutually upon expiry or prior to the expiry of the term of the Agreement.

**4. WORKING METHODOLOGY**

**4.1. Relationship Management**

Academic Partner will designate one person as "Relationship Manager" to whom all pertinent communications within the purview of this Agreement will be addressed. In particular the "Relationship Manager" will be responsible for providing the assistance to JCL on all aspects of the relationship. JCL will in turn designate one of its employees or associates as its "Relationship Manager (JCL)". Any change in these designated personnel shall be agreed and intimated in writing to the parties from time to time.

**4.2 Delivery Standards and Practices**

Memorandum of Agreement between Jehangir Clinical Development Centre's JCL and Indira College of Pharmacy, Tathawade, Pune.

JCL will deliver the course in accordance with the course structure design as decided by JCL and will circulate related study material to the students. JCL will also conduct the examination and evaluation thereof. The rights of alternation, modification in the course design and course material will be reserved by JCL.

4.3 Academic Partner will carry out the necessary promotional activities for the course wherein JCL staff will counsel the aspirants for the course.

4.4 JCL will provide a certification to the Students for the program after successful completion of the course by the students and passing the examination conducted by JCL.

**5. FINANCIALS**

5.1 Total Fees to students for a e-learning course in Professional Certification in Clinical Research (subject to revisions which may be applicable from time to time) -

- MRP of the course - Rs. 15,000 + Taxes (Currently Taxes are 18% GST)

5.2 Total Fees to students for Online live interactive batch for Post Graduate Diploma in Clinical Research (subject to revisions which may be applicable from time to time) -

- MRP of the course - Rs. 25,000 + Taxes (Currently Taxes are 18% GST)

**6. INTELLECTUAL PROPERTY**





6.1 The design of the course and the study material of the course will be the sole intellectual property of JCL. Appendix I defines design and modules covered and mutually agreed by both the Parties. Subject to the terms and conditions of this Agreement, the Parties agree that the Intellectual Property shall at all times, during the Term of this Agreement and thereafter be in the ownership, possession and control of JCL. The Parties agree that nothing in this Agreement shall be construed as granting any right, title or interest to Academic Partner, whether during the Term of this Agreement or thereafter. The Parties hereby agree that the JCL shall individually reserve the right to transfer, assign and convey this Intellectual Property. For the purpose of this Agreement, Intellectual Property includes without limitation ideas, concepts, creations, discoveries, inventions, improvements, know how, trade or business secrets; trademarks, service marks, designs, utility models, tools, devices, models, methods, procedures, processes, systems, principles, algorithms, works of authorship, flowcharts, drawings, books, papers, models, sketches, formulas, teaching techniques, electronic codes, proprietary techniques, research projects, and other confidential and proprietary information, computer programming code, databases, software programs, data, documents, instruction manuals, records, memoranda, notes, user guides; in either printed or machine-readable form, whether or not copyrightable or patentable, or any written or verbal instructions or comments; which is related to the business of the Parties. The Intellectual Property rights in and to the course including but not limited to the design, content, conduct, delivery, study material, notes, presentations, videos etc. solely rest JCL.


**7. TERMINATION**

7.1 Either party may terminate this Agreement forthwith on giving notice in writing to the other party if

7.1.1 commits any material breach of any term of this Agreement.

Memorandum of Agreement between Jehangir Clinical Development Centre, JCL and Indra College of Pharmacy,  
Tathawade, Pune.





purposes of this Agreement and to no other person or entity, whether for its own benefit or for the benefit of any other person or entity.

8.3 Both Parties further agree to return all Confidential Information in its possession, control or custody immediately upon termination or expiration of this Agreement.

8.4 Both Parties agree that in the event, either Party is required to disclose Confidential Information to any competent authority or under any applicable law, either Party shall intimate the other Party with regard to the disclosure of the Confidential Information and shall assist the other Party in obtaining a protective order. However, in the event of failure to obtain such an order, either Party shall disclose the Confidential Information to such competent authority. The Parties shall limit disclosure of the Confidential Information.

8.5 Either Party shall ensure that it shall in no manner whatsoever indulge in the disclosure or dissemination of Confidential Information to any third party with the prior written approval of the other Party. In the event of unauthorized disclosure and dissemination of Confidential Information by either Party to any third party, the same would cause irreparable injury to the other Party and no amount of monetary compensation would cure such an injury caused and such Party reserves the right to get an injunctive order from the court of competent jurisdiction preventing the other Party from making such unauthorized disclosures. Further, either Party reserves the right to immediately terminate the Agreement in the event of breach of the confidentiality obligation by the other Party.

8.6 For the purpose of this Agreement, Confidential Information means and includes, without limitation, any trade secrets, knowledge, data or other proprietary or confidential information relating to products, processes, know-how, intellectual property, designs, developmental or experimental work, ideas, innovations, computer programs, computer artwork, databases, other original works or authorship, customer and supplier lists, business plans, marketing plans and strategies, financial information or other subject matter pertaining to any business of the either Party or any of the either Party's customers, suppliers, consultants or licensees, which may or may not be registered under any of the laws pertaining to protection of intellectual property rights in the country; personnel data information and materials developed, collected or used by the personnel of either Party information related to deals or proposed deals to be entered into by either Party information disclosed by third parties with which either Party may have a business relationship, business practices and all other proprietary information, methods and property of either Party whether in tangible and/or intangible form.

**9. REPRESENTATIONS AND WARRANTIES**

9.1 Each of the Party represents and warrant that:




9.1.1 It has power to execute and enter into this Agreement and it has full right, capacity and authority to perform its obligations under this Agreement which when executed will constitute valid and binding obligations on it in accordance with its terms.

9.1.2 The entry and delivery of, and the performance by it of this Agreement will not result in any breach of any provision of applicable law, its constitutional documents, any other agreement and / or any court order, judgment, injunction, award, decree or writ that is binding on it and / or its assets, or result in any claim by a third party against the other Party;

9.1.3 The execution and delivery of this Agreement and the transactions contemplated hereby have been duly approved and authorized by all requisite actions and no other actions (corporate, statutory or otherwise) on its part are necessary.

9.1.4 It has understood the terms of this Agreement and a copy of the Agreement has been provided to it;

Memorandum of Agreement between Jehangir Clinical Development Centre, 108 and Indira College of Pharmacy, Tathawade, Pune.

9.1.5 It has executed this Agreement of its free will and without relying on any statements made by the other Party or its representatives, agents or affiliates etc.;

9.1.6 The Agreement in all respects is reasonable and necessary to protect the legitimate business interests of the Parties.

**10. INDEMNIFICATION**

10.1 Either Party hereby agrees to indemnify the other Party and each of its respective officers, employees, representatives attorneys, affiliates and agents and save and hold them harmless, from and in all respect of, including but not limited to all liabilities, obligations, damages, penalties, claims, actions, judgments, suits, fees, costs and expenses, including legal fees incurred in connection with or resulting from any claim, action or demand against them that arises out of or in any way relates to (i) any breach of any warranty or obligation under this Agreement; or (ii) negligence, fraud, misconduct or willful default on the part of the either Party during the term of this Agreement; (iii) any breach of any third party's rights; (iv) any breach of the terms and conditions of this Agreement.

**11. NON-COMPETE**

11.1 Academic Partner acknowledges and agrees that under no circumstances during the term of this Agreement and thereafter for a period of 3 years shall Academic Partner directly or indirectly compete with the business of JCL.

**12. NON-SOLICITATION**




12.1 Academic Partner covenant and undertake that Academic Partner shall not during the Term of this Agreement and for a period of [3.] years after the termination or expiry of this Agreement, directly or indirectly: (a) attempt in any manner to solicit any current clients/students of JCL or any firm, association or corporation or other entity which the JCL contacted or otherwise dealt business of the type carried on, or proposed to be carried on, by JCL; (b) attempt to persuade any person, firm or entity, which is a client/students (for the purpose of this Clause, client/students would also include potential client/students, where discussions have been held during the period of the JCL's engagement with Academic Partner with a view to conducting business with JCL to cease doing business or to reduce the amount of business which any such customer has customarily done or might propose doing with JCL whether or not the relationship between Parties and such client/students was originally established in whole or in part through its efforts; (c) employ, solicit, incite, canvass or attempt to employ or assist anyone else to employ any person who is in the employment/traineeship of JCL or was in the employment/traineeship of JCL at any time during the preceding 12 calendar months. Further, the Party shall not during such period solicit, incite or in any other way encourage other employees/trainees of JCL to terminate their respective contracts of employment/traineeship with JCL.

**13. NOTICES**

13.1 All notices which are required to be given hereunder shall be in writing and shall be sent to the address or by way of email of the recipient set out in this Agreement, or such other address as the recipient may designate by notice given in accordance with the provisions of this Clause. The addresses and email ids shall be as follows:

If to JCL:  
 Attention: Mr. Pathik Divate  
 Address: Jehangir Hospital Premises, 32 Sasoon Road, Pune - 411 001.

Memorandum of Agreement between Jehangir Clinical Development Centre's JCL and Indira College of Pharmacy, Tathawade, Pune.

purposes of this Agreement and to no other person or entity, whether for its own benefit or for the benefit of any other person or entity.

8.3 Both Parties further agree to return all Confidential Information in its possession, control or custody immediately upon termination or expiration of this Agreement.

8.4 Both Parties agree that in the event, either Party is required to disclose Confidential Information to any competent authority or under any applicable law, either Party shall intimate the other Party with regard to the disclosure of the Confidential Information and shall assist the other Party in obtaining a protective order. However, in the event of failure to obtain such an order, either Party shall disclose the Confidential Information to such competent authority. The Parties shall limit disclosure of the Confidential Information.

8.5 Either Party shall ensure that it shall in no manner whatsoever indulge in the disclosure or dissemination of Confidential Information to any third party with the prior written approval of the other Party. In the event of unauthorized disclosure and dissemination of Confidential Information by either Party to any third party, the same would cause irreparable injury to the other Party and no amount of monetary compensation would cure such an injury caused and such Party reserves the right to get an injunctive order from the court of competent jurisdiction preventing the other Party from making such unauthorized disclosures. Further, either Party reserves the right to immediately terminate the Agreement in the event of breach of the confidentiality obligation by the other Party.

8.6 For the purpose of this Agreement, Confidential Information means and includes, without limitation, any trade secrets, knowledge, data or other proprietary or confidential information relating to products, processes, know-how, intellectual property, designs, developmental or experimental work, ideas, innovations, computer programs, computer artwork, databases, other original works or authorship, customer and supplier lists, business plans, marketing plans and strategies, financial information or other subject matter pertaining to any business of the either Party or any of the either Party's customers, suppliers, consultants or licensees, which may or may not be registered under any of the laws pertaining to protection of intellectual property rights in the country; personnel data information and materials developed, collected or used by the personnel of either Party information related to deals or proposed deals to be entered into by either Party information disclosed by third parties with which either Party may have a business relationship, business practices and all other proprietary information, methods and property of either Party whether in tangible and/or intangible form.

**9. REPRESENTATIONS AND WARRANTIES**

9.1 Each of the Party represents and warrant that:




9.1.1 It has power to execute and enter into this Agreement and it has full right, capacity and authority to perform its obligations under this Agreement which when executed will constitute valid and binding obligations on it in accordance with its terms.

9.1.2 The entry and delivery of, and the performance by it of this Agreement will not result in any breach of any provision of applicable law, its constitutional documents, any other agreement and / or any court order, judgment, injunction, award, decree or writ that is binding on it and / or its assets, or result in any claim by a third party against the other Party;

9.1.3 The execution and delivery of this Agreement and the transactions contemplated hereby have been duly approved and authorized by all requisite actions and no other actions (corporate, statutory or otherwise) on its part are necessary.

9.1.4 It has understood the terms of this Agreement and a copy of the Agreement has been provided to it.

Memorandum of Agreement between Jehangir Clinical Development Centre's (JCDC) and Indira College of Pharmacy, Tathawade, Pune

Email id: pathik@jcdc.co.in

If to the Academic Partner:  
 Attention: Dr. (Mrs.) Anagha Joshi  
 Address: Indira College of Pharmacy, 89/2A, Nirmaya, New Mumbai – Pune Highway, Tathawade, Pune 411033.  
 Email id: ajoshi@indiraedu.com

13.2 Any such notice may be delivered by hand or by first class pre-paid letter or fax and shall be deemed to have been served if by hand when delivered, if by first-class post 48 hours after posting, and if by fax when confirmation of proper transmission has been received. If there is any change in addresses of either Party, the Parties shall intimate the same to the other Party within 7 (seven) days from the date of such change in the address.

**14. HEADING**

14.1 The headings to the Clauses of this Agreement are for ease of reference only and shall not affect the interpretation or construction of this Agreement.

**15. DISPUTE RESOLUTION**

15.1 All disputes, differences of opinion and controversies arising between the Parties out of this Agreement shall be resolved amicably, failing which they shall be finally settled by a sole arbitrator appointed by the Parties. The arbitration shall be conducted in accordance with the Arbitration and Conciliation Act, 1996 or any amendment thereof for the time being in force. Arbitration proceedings shall take place in Pune, India.

15.1.1 The award of the arbitrator shall be a reasoned award and shall be final and binding on the Parties. The arbitration proceedings shall be conducted and the award shall be rendered in English language.

15.1.2 During the pendency of any arbitration proceedings, the Parties shall continue to perform their respective obligations under this Agreement.

15.2 Subject to above, the Courts at Pune shall have exclusive jurisdiction in respect of all matters arising under or out of this Agreement.

**16. ENTIRE AGREEMENT**

16. This Agreement constitutes the entire agreement between the parties and the terms and conditions contained herein shall apply for the conduct of the course. No modification of these terms and conditions shall be effective unless accepted in writing and signed by duly authorized representatives of the Parties. This Agreement is in addition to the course structure and payment terms agreed by the Parties from time to time.

**17. APPLICABLE LAW**

17.1 This Agreement shall be governed by Indian law. The Pune courts will have non-exclusive jurisdiction to settle any disputes or claims which may arise out of or in connection with the Agreement for which purpose all parties agree to submit to its jurisdiction.

Memorandum of Agreement between Jehangir Central Development Centre's JCL and Indira College of Pharmacy, Tathawade, Pune.

*(Signature)*  
 PRINCIPAL  
 Indira College of Pharmacy  
 Tathawade, Pune - 411 033

**18. EFFECTIVE DATE**

18.1 This Agreement will be effective from 1<sup>st</sup> February, 2021.

**19. AMENDMENT TO THE AGREEMENT**

19.1 This Agreement shall not be amended, altered or modified, or any provision herein shall not be waived except by an instrument in writing expressly referring to this Agreement and signed by the duly authorized representatives of the Parties, and no verbal Agreement or conduct of any nature relating to the subject matter hereof or to the relationship between the Parties will be considered valid and enforceable.

**20. ENFORCEABILITY OF AGREEMENT**

20.1 If any part, or provision of this Agreement not being of a fundamental nature, is held illegal or unenforceable, the validity or enforceability of the remainder of this Agreement shall not be affected if such part, term or provision is severable from the rest of this Agreement without altering the essence of this Agreement. If such part, term or provision is not so severable, then the whole of this Agreement shall stand terminated, unless the Parties thereupon negotiate in good faith in order to agree to the terms of a mutually satisfactory provision, achieving as nearly as possible the same commercial effect, to be substituted for the provision so found to be invalid, illegal or unenforceable.

**21. SURVIVABILITY**

21.1 The terms of following Sections shall survive termination of this Agreement:

1. Intellectual Property (Clause 6),
2. Termination (Clause 7),
3. Confidential Information (Clause 8),
4. Notices (Clause 13),
5. Survivability (Clause 21),
6. Indemnity (Clause 10)

**22. FORCE MAJEURE**

22.1 If either party is unable to perform its obligations or to enjoy the benefits of this Agreement because of any judicial Governmental decree, regulation or other direction not the fault of the Party who has been so affected, fire, flood, earth quake, failure of any satellite or other telecommunications link, civil unrest, terrorist attack or any natural disaster or Act of God (hereinafter referred to as the "Force Majeure Event") the Party who has been so affected shall immediately give notice to the other party and shall do everything possible to resume performance. Upon receipt of such notice, this Agreement thereby affected shall be suspended and, at its discretion, either Party may make arrangements to resume performance of the Agreement. If the period of non-performance exceeds 15 calendar days from the receipt of notice of the Force Majeure Event, unless arrangements for resumption of performance of the agreement have been made, the Party who has not been so affected may, by giving written notice, terminate this Agreement.

IN WITNESS WHEREOF, the parties have entered into this Agreement and do each hereby warrant and represent that their respective signatory whose signature appears below has been and is on the

Memorandum of Agreement between Jahangir Clinical Development Centre's JCL and Indira College of Pharmacy, Tathawade, Pune

Indira College of Pharmacy  
Tathawade, Pune +91 20 2733 6333

date of this Agreement duly authorized by all necessary and appropriate corporate action to sign this Agreement.

Name: Mr. Pathik Divate  
Title: CEO, JCDC  
Sign: \_\_\_\_\_  
Date: \_\_\_\_\_

For and on behalf of Jehangir Center for Learning, Pune

Name: Dr. (Mrs.) Anagha Joshi  
Title: Principal, Indra College of Pharmacy, Tathawade, Pune  
Sign: \_\_\_\_\_  
Date: \_\_\_\_\_

For and on behalf of Indra College of Pharmacy, Tathawade, Pune

**Appendix I**

**Course Features:**

(Professional Certification in Clinical Research)

1. Experienced faculty who are eminent members of Clinical research industry
2. Self-Paced course in E-learning format
3. 2-3 months Theory training (the time taken by every student can vary as it is self-paced online course)
4. Includes introduction to Clinical Data Management and Pharmacovigilance

Memorandum of Agreement between Jehangir Clinical Development Centre's CLS and Indra College of Pharmacy, Tathawade, Pune

5. Includes Medical writing: Protocol development and CRF Design.

6. Periodic Doubt clearing sessions.

**(Post Graduate Diploma In Clinical Research)**

1. Experienced faculty who are eminent members of Clinical research industry.

2. Live interactive batch. (Using any e-meeting app)

3. 3-4 months theory training (online) (Weekend batch).

4. Includes introduction to Clinical Data Management and Pharmacovigilance

5. Includes Medical writing: Protocol development and CRF Design.

**Course Content:**

1. Introduction to Clinical Research.

2. Evolution of GCP.

3. Principles of GCP + Practical Application + Case Studies.

4. Phases of clinical trials and drug development process.

5. Medical Terminologies in Clinical Research.

6. Drug & Cosmetic Act 2019.

7. Informed Consent, Elements and Documentation.

8. Essential documents in clinical research.




9. Source Documentation.

10. Overview of Trial Design and Protocol Writing

11. AE/SAE Reporting

12

Memorandum of Agreement between Jehangir Clinical Development Centre's ICL and Indira College of Pharmacy, Tathawade, Pune.







## SUMMARY



Shree Chanakya Education Society's  
**Indira College of Pharmacy, Pune**  
 "Redefining Pharmacy Education"

**NAAC: B++**

Approved by PCI, AICTE, New Delhi, Affiliated to SPPU & MSBTE, Recognized by Govt. of Maharashtra

### SUMMARY

Title: Activities carried out under MOU(Jehangir Hospital )			
S.No.	Name of the Activity	Topic	Class
1	Guest Lecture	Clinical research overview and opportunities	Final Year B. Pharm, Fourth Year Pharm D, Fifth Year Pharm D
2	Guest Lecture	Introduction to Clinical Research	Final Year B. Pharm, Fourth Year Pharm D, Fifth Year Pharm D
3	Certification Course	Clinical Research	Pharm D



Dr. Anagha M Joshi

**PRINCIPAL**  
 (Principal)  
 Indira College of Pharmacy  
 Tathawade, Pune - 411 033



## Guest Lecture

Criterion – Research, Innovations &amp; Extension

SSR

2022

## Guest Lecture



## Shree Chanakya Education Society's

## INDIRA COLLEGE OF PHARMACY, PUNE

(Approved by Pharmacy Council of India, All India Council for Technical Education, New Delhi, Directorate of Technical Education (MS) and Government of Maharashtra- Affiliated to Savitribai Phule Pune University, Accredited by NAAC B++ Grade)

ID No. PU/PN/Pharmacy/258/2006

AISHE Code- C-

41396

Ref No. SCES/ ICP/ 2021-2022/  
2021Date: 09<sup>th</sup> September,

To,  
Dr Ravindra Ghooi  
Chairman,  
Jehangir clinical development centre,  
Pune, Maharashtra

Sub: Sessions on "Clinical research overview and opportunities"

Dear Sir,

Indira College of Pharmacy was established under the auspices of Shree Chanakya Education Society. It is one of the most reputed Educational organizations which has created its own forte in the educational arena around Pune in a very small span and is branded as a premier educational institution.

We reckon that you are one of the few self-motivated, dedicated and experienced professionals, nurturing professional & ethical values and boosting the noble profession of Health Sciences in the country.

We are privileged to invite you at **Indira College of Pharmacy, Tathawade, Pune – 411033** for delivering Online session. We request you to conduct online sessions on "Clinical research overview and opportunities" at our institute on "Monday, 13<sup>th</sup> September 2021.

We would be honored if you kindly accept our invitation and spare your valuable time to guide our students.

Thanking you,



Yours faithfully,

  
**PRINCIPAL**  
(Dr. Anugha Joshi)  
**Indira College of Pharmacy**  
Tathawade, Pune - 411 033

---

*SCES'S Indira College of Pharmacy, Pune*

**Guest Lecture**

Criterion – Research, Innovations &amp; Extension

SSR

2022



Guest Lecture

**Shree Chanakya Education Society's****INDIRA COLLEGE OF PHARMACY, PUNE**

(Approved by Pharmacy Council of India, All India Council for Technical Education, New Delhi, Directorate of Technical Education (MS) and Government of Maharashtra- Affiliated to Savitribai Phule Pune University, Accredited by NAAC B++ Grade)

ID No. PU/PN/Pharmacy/258/2006

AISHE Code- C-

41396

Ref No. SCES/ ICP/ 2021-2022/

Date: 13<sup>th</sup> September, 2021

To,  
Dr Ravindra Ghooi  
Chairman,  
Jehangir clinical development centre,  
Pune, Maharashtra

Sub: Sessions on “Clinical research overview and opportunities”

Dear Sir,


We would like to express our sincere thanks to you. It was a unique opportunity for all the students to have an interaction with you. We are extremely thankful to you for sparing your valuable time and delivering such an excellent session to our students on “Clinical research overview and opportunities”

We positively look forward for a long term association with you and for your valuable guidance in mentoring our students.

Thanking you,

Yours faithfully,





  
(Dr. Anagha Joshi)  
Principal  
Indira College of Pharmacy  
Tathawade, Pune - 411 033

SCES'S Indira College of Pharmacy, Pune

Guest Lecture



*Shree Chanakya Education Society's*  
**INDIRA COLLEGE OF PHARMACY, PUNE**  
*"Redefining Pharmacy Education"*



*MJK*

PRINCIPAL  
Indira College of Pharmacy  
Tathawade, Pune - 411033



Guest Lecture




Shree Chanakya Education Society's  
**Indira College of Pharmacy, Pune**

"Redefining Pharmacy Education"

**NAAC : B++**

Approved by PCI, AICTE, New Delhi, Affiliated to SPPU & MSBTE, Recognized by Govt. of Maharashtra

SHREE CHANAKYA EDUCATION SOCIETY'S  
**INDIRA COLLEGE OF PHARMACY**  
Approved by All India Council for Technical Education, and Pharmacy Council of India, New Delhi,  
Recognized by Govt. of Maharashtra, Directorate of Technical Education (MS)  
Affiliated to Savitribai Phule Pune University & Accredited by NAAC - B++  
ID No. PU/PN/Pharmacy/258/2006



Date: 16/01/2021

To,  
Dr. Uma Divate,  
Jehangir Clinical development centre,  
Pune.


Sub: Session on "Introduction to Clinical research"



Dear Madam,


We would like to express our sincere thanks to you. It was a unique opportunity for all the students to have an interaction with you. We are extremely thankful to you for sparing your valuable time and delivering such an excellent session to the B. Pharm and Pharm D. students on "Introduction to Clinical research".

We positively look forward for a long term association with you and for your valuable guidance in mentoring our students.

Thanking you,

Yours faithfully,  
  
(Dr. Anagha Joshi)  
Principal





  
PRINCIPAL  
Indira College of Pharmacy  
Tathawade, Pune - 411033.

Hiramay, 88/2 - A, New Pune - Mumbai Highway, Tathawade, Pune - 411 033, India.  
Tel. +91-20-22933279, 66759603, 06 Fax +91-20-66769601 E-mail: admin@indiraicp.edu.in Website: www.indiraicp.edu.in

Guest Lecture



Shree Chanakya Education Society's  
**INDIRA COLLEGE OF PHARMACY, PUNE**  
*"Redefining Pharmacy Education"*





*Myek*  
**PRINCIPAL**  
 Indira College of Pharmacy  
 Wade, Pune - 41103



Guest Lecture



*Shree Chanakya Education Society's*  
**INDIRA COLLEGE OF PHARMACY, PUNE**  
*"Redefining Pharmacy Education"*



*mych*  
PRINCIPAL  
Indira College of Pharmacy  
Pune - 411033.



Certification Course


Criterion – Research, Innovations & Extension

SSR

2022



Certification Course



*Myel*  
PRINCIPAL  
Indira College of Pharmacy  
Tathawade, Pune - 411 033

SCES'S Indira College of Pharmacy, Pune

[Back to Index](#)



## MOU

### V-Ensure Pharma Technologies Pvt Ltd

Date: 01/07/2021

#### Memorandum of Understanding between V-Ensure Pharma Technologies Pvt Ltd, and Indira College of Pharmacy

V-Ensure Pharma Technologies Pvt Ltd. (V-Ensure) and SCES' Indira College of Pharmacy (ICP) hereby agree to enter into a Memorandum of Understanding (MoU) for academic and professional collaboration with the purpose of mutual benefit. ICP was established in 2006 and since then offers the courses of B. Pharmacy, M.Pharmacy, and Ph.D. V-Ensure has been in the business of pharmaceuticals for last 11 years. Both parties agree that giving exposure to the students to cutting edge technologies and practical projects will enable students to secure jobs as well as pursue entrepreneurship options. Both parties agree to the following terms

#### **Internships and Placements and Corporate Relations:**

- a. Both organizations will work closely to come up with models of regular engagement between ICP students and Faculties and V-Ensure trainers, developers and project managers.
- b. V-Ensure will offer training and internship to graduates and post-graduate students of ICP with a minimum stipend from commencement of the project, and as per their performance may offer placement.
- c. V-Ensure will conduct the placement drives at ICP to recruit fresh graduates and post-graduates at their R&D center and manufacturing plant.

#### **Research:**

- a. V-Ensure and ICP will work together on projects in areas of mutual interest. The projects will be executed partly at V-Ensure and partly in the college after approval of the research proposal by V-Ensure.
- b. The research work undertaken by V-Ensure will be published in reputed journals under the ownership of both the parties on approval from V-Ensure.
- c. V-Ensure will allow the students of ICP to use sophisticated instruments and equipment on a prior notice for the research work. This kind help extended by V-Ensure will be duly acknowledged by the students in their research publications and dissertation.

#### **Industry Institute Partnership:**

- a. ICP believes in inviting and involving Corporate Professionals for Board of Advisors, Guest Lectures, Workshops, Seminars and similar events for which expert/s are required for enhancing knowledge, skills and attitude of Faculty & Students. To achieve this objective, whenever possible, V-Ensure will allow their professional employees to visit ICP. ICP will also allow their faculty to visit V-Ensure for sharing their knowledge and expertise in the area of interest for V-Ensure.

**Term of MOU:**


This MOU shall be valid for a period of 3 years from the commencement date of 01/07/2021.

**Contact Persons**

Dr.(Mrs.) Madhur Kulkarni will be the contact person for ICP to initiate, manage or execute any joint activities between ICP and Pradeep Arya will be the contact person for V-Ensure.

  
By: Head HR - V-Ensure  
Name: PRADEEP ARYA



  
By: Principal - ICP  
Name: Dr.(Mrs.) Anagha Joshi



Date: \_\_\_\_\_

Date: \_\_\_\_\_

#### **NON-DISCLOSURE AGREEMENT**

THIS NON-DISCLOSURE AGREEMENT (this "Agreement") is made and entered into as of 1<sup>st</sup> July 2021 between V-Ensure Pharma technologies Pvt Ltd., Navi Mumbai. (V-Ensure) and SCES's Indira College of Pharmacy, New Mumbai-Pune Highway, Tathwade, Pune, Maharashtra – 411033 (ICP) and **Purpose: V-Ensure and ICP wish to explore Opportunities in Training, Student Corporate Placement, Research, & consultancy of mutual interest and in connection with this opportunity wishes to execute this Non-Disclosure Agreement ("NDA").**

**1. Confidential Information:** Confidential information means any information disclosed to by one party to the other, either directly or indirectly in writing, orally or by inspection of tangible or intangible objects, including without limitation documents, business plans, source code, software, hardware, application and uses of hardware and software, documentation, financial analysis, marketing plans, customer names, customer list, customer data. Confidential Information may also include information disclosed to a party by third parties at the direction of a Disclosing Party. Confidential Information shall not, however, include any information which the Receiving party can establish (i) was publicly known and made generally available in the public domain prior to the time of disclosure; (ii) becomes publicly known and made generally available after disclosure through no action or inaction of Receiving Party; or (iii) is in the possession of Receiving Party, without confidentiality restrictions, at the time of disclosure by the Disclosing Party as shown by Receiving Party's files and records immediately prior to the time of disclosure. The party disclosing the Confidential Information shall be referred to as "Disclosing Party" in the Agreement and the party receiving the Confidential Information shall be referred to as "Receiving Party" in the Agreement.

**2. Non-use and Non-disclosure:** The Receiving Party agrees not to use any Confidential Information for any purpose except to evaluate and engage in discussions concerning a potential business relationship between the parties hereto. Receiving Party agrees not to disclose any Confidential Information to third parties or to its employees, except to those employees who are required to have the information in order to evaluate or engage in discussions concerning the contemplated business relationship. The Receiving Party shall not reverse engineer, disassemble or decompile any prototypes, software or other tangible objects which embody the Disclosing Party's Confidential Information and which are provided to the Receiving Party hereunder.

**3. Maintenance of Confidentiality Information:** The Receiving Party agrees that it shall take all reasonable measures to protect the secrecy of and avoid disclosure and unauthorized use of the Confidential Information. Without limiting the foregoing, Receiving Party shall take at least those measures that Receiving Party takes to protect its own most highly confidential information and shall have its employees, if any, who have access to Confidential Information sign a non-use and non-disclosure agreement in content substantially similar to the provisions hereof, prior to any disclosure of Confidential Information to such employees. The Receiving Party shall not make any copies of Confidential Information unless the same are previously approved in writing by the Disclosing Party. The Receiving Party shall reproduce the Disclosing Party's proprietary rights notices on any such approved copies, in the same manner in which such notices were set forth in or on the original. The Receiving Party shall immediately notify the Disclosing Party in the event of any unauthorized use or disclosure of the Confidential Information.

**4. No Obligation:** Nothing herein shall obligate either party to proceed with any transaction between them, and each party reserve the right, in its sole discretion, to terminate the discussions contemplated by this Agreement concerning the business opportunity.

**5. No Warranty:** ALL CONFIDENTIAL INFORMATION IS PROVIDED "AS IS", NEITHER PARTY MAKES ANY WARRANTIES, EXPRESS, IMPLIED OR OTHERWISE, REGARDING ITS ACCURACY, COMPLETENESS OR PERFORMANCE.

**6. Return of Materials:** All documents and other tangible objects containing or representing Confidential Information and all copies thereof which are in the possession of Receiving Party shall be and remain the property of the Disclosing Party and shall be promptly returned to the Disclosing Party upon the Disclosing Party's request.

**7. No License:** Nothing in this Agreement is intended to grant any rights to either party under any patent, mask work right or copyright of Company, nor shall this Agreement grant Receiving Party any rights in or to Confidential Information except as expressly set forth herein.

**8. Term:** This Agreement shall survive for a period of 3 years from the date of disclosure of the Confidential Information.

**9. Remedies:** The Receiving Party agrees that any violation or threatened violation of this Agreement will cause irreparable injury to the Disclosing Party, entitling the Disclosing Party to obtain injunctive relief in addition to all legal remedies.

10. **Miscellaneous:** This Agreement shall bind and inure to the benefit of the parties hereto and their successors and assigns. This document contains the entire agreement between the parties with respect to the subject matter hereof. Any failure to enforce any provision of this Agreement shall not constitute a waiver thereof or of any other provision hereof. This Agreement may not be amended, nor any obligation waived, except by a writing signed by both parties hereto. The parties have executed this Nondisclosure Agreement as of the date first above written.

[V-Ensure]

[ICP]

By:  Head HR 

By:  Principal



Name: Mr. Pradeep Arya

Name: Dr. Anagha Joshi

Date: \_\_\_\_\_

Date: \_\_\_\_\_

## SUMMARY



*Shree Chanakya Education Society's*  
**Indira College of Pharmacy, Pune**  
*"Redefining Pharmacy Education"*


**NAAC: B++**

Approved by PCI, AICTE, New Delhi, Affiliated to SPPU & MSBTE, Recognized by Govt. of Maharashtra

### SUMMARY

Title: Activities Carried out under MOU (V-Ensure)				
S.No.	Name of the Activity	Name of the student	Internship Period	Branch
1.	Internship	Apurva Ramesh Pol	6 months	Pharmaceutics
2.	Internship	Hrishikesh Motilal Mahale	6 months	Pharmaceutics
3.	Internship	Surbhi Narendra Sahu	6 months	Pharmaceutics
4.	Internship	Krishna Narendra Yerawal	4.5 Months	QA
5.	Internship	Uniket Manohar Gosavi	4.5 Months	QA
6.	Internship	Vaishnavi Kamalakar kamthe	6 months	QA
7.	Internship	Manisha Subhash Bade	6 months	QA
8.	Internship	Sachin Dattatray Patil	6 months	QA
9.	Internship	Pallavi Ganesh chiwhane	6 months	QA
10.	Offer Letter	Vaibhav Kharbe	-	Pharmaceutics
11.	Offer Letter	Sheetal Mahadkar	-	Pharmaceutics



  
 Dr. Anagha M Joshi  
**PRINCIPAL**  
 Indira College of Pharmacy  
 Tathawade, Pune - 411 033

### Internship

Criterion - III – Research, Innovations & Extension

SSR

2022




**V-ENSURE**  
V-Ensure Pharma Technologies Pvt. Ltd.

Date: 22<sup>nd</sup> March 2022


#### TO WHOM IT MAY CONCERN

This is to certify that Miss Apurva Ramesh Pol student of SCES's Indira College of Pharmacy has successfully completed Training program from 20<sup>th</sup> September 2021 to 22<sup>nd</sup> March 2022 in Formulation Research Department of our R&D center situated at A-63, Khairane. During the period of her Training program with us she was found Punctual, Hardworking and inquisitive. We wish her a successful and good career.

For V-Ensure Pharma Technologies Pvt. Ltd.

  
Mr. Saswat Padhi  
(Assistant General Manager)



  
PRINCIPAL  
Indira College of Pharmacy  
Tathawade, Pune - 411033.

Regd. & Corp. Off: A-63, TTC Industrial Area, MIDC Khairne, Navi Mumbai - 400 705 Tel: +91 22 27633333 / 0007 CIN No.: U74999MH2010PTC205669  
Mfg. Unit: Plot No. N-32, Additional Patalganga Industrial Area, Village/City: Karade Butrik, Taluka: Parvel, Dist.: Raigad. Pin - 410206. Tel. No. 7030227304  
www.v-ensure.com | info@v-ensure.com

SCES'S Indira College of Pharmacy, Pune

### Internship

Criterion - III – Research, Innovations & Extension      SSR      2022

**V-ENSURE**  
V-Ensura Pharma Technologies Pvt. Ltd.

Date: 22<sup>nd</sup> March 2022

**TO WHOM IT MAY CONCERN**

This is to certify that Mr. Hrishikesh Motilal Mahale student of SCES's Indira College of Pharmacy has successfully completed Training program from 26<sup>th</sup> September 2021 to 22<sup>nd</sup> March 2022 in Formulation Research Department of our R&D center situated at A-63, Khairans.

During the period of his Training program with us he was found Punctual, Hardworking and Inquisitive. We wish him a successful and good career.

For V-Ensura Pharma Technologies Pvt. Ltd.

  
Mr. Shripati Padil  
(Assistant General Manager)



  
PRINCIPAL  
Indira College of Pharmacy  
Tathawade, Pune - 411033.



Regd. & Corp. Off: A-63, TIC Industrial Area, MIDC Khairans, Haveli Mundal - 420 205. Tel: +91 22 27530033 / 000 / CIN No: U14990W1201GPIC293309  
Mfg. Unit: Plot No. 11/32, Additional Patajanga Industrial Area, Village/City Karada Budsh, Taluka: Panvel, Dist: Raigad, Pin - 410 205, Tel. No. 700021204  
www.v-ensura.com | info@v-ensura.com

SCES'S Indira College of Pharmacy, Pune

### Internship

Criterion - III – Research, Innovations & Extension

SSR

2022




**V-ENSURE**  
V-Ensure Pharma Technologies Pvt. Ltd.

Date:-22<sup>nd</sup> March 2022


#### TO WHOM IT MAY CONCERN

This is to certify that Miss Surbhi Narendra Sahu student of SCES's Indira College of Pharmacy has successfully completed Training program from 20<sup>th</sup> September 2021 to 22<sup>nd</sup> March 2022 in Formulation Research Department of our R&D center situated at A-63, Khairane.  
During the period of her Training program with us she was found Punctual, Hardworking and inquisitive. We wish her a successful and good career.

For V-Ensure Pharma Technologies Pvt. Ltd.

  
Mr. Saswat Padhi  
(Assistant General Manager)



  
PRINCIPAL  
Indira College of Pharmacy  
Tathawade, Pune - 411033.



Regd. & Corp. Off: A-63, TTC Industrial Area, MIDC Khairane, Navi Mumbai - 400 705. Tel: +91 22 27630033 / 0007 CIN No.: U74990MH2010PTC036969  
Mfg. Unit: Plot No. N-32, Additional Palalganga Industrial Area, Village/City: Karade Budruk, Taluka: Panvel, Dist.: Raigad. Pin - 410 206. Tel. No. 703027304

www.v-ensure.com | info@v-ensure.com

SCES'S Indira College of Pharmacy, Pune



### Internship

Criterion - III – Research, Innovations & Extension      SSR      2022     

V-Ensure Pharma Technologies Pvt. Ltd.

**TO WHOM SO EVER IT MAY CONCERN**

This letter is to certify that Mr. Krishna Narendra Yerawar, a 2<sup>nd</sup> Year M.Pharm student of SCES's Indira College of Pharmacy Pune, has successfully completed 4 Months 15 days project training program with V-Ensure Pharma Technologies Private Limited. His training tenure at R&D Center, Navi Mumbai was from 12<sup>th</sup> January, 2022 to 25<sup>th</sup> May 2022.

He received training under the Guidance of Mr. Narayan Raktade – Head of Analytical Research & Development Department.

During the span, we found his enthusiastic and eager to learn. He was actively and diligently involved in the task assigned to him. Feedback and evaluation prove that he learned keenly. Moreover, his interpersonal and communication skills are good, which was evident from his project report.

We wish him a bright future.

For V-Ensure Pharma Technologies Pvt. Ltd.

**Pradeep Arya**  
 HR Head


**PRINCIPAL**  
 Indira College of Pharmacy  
 Tathawade, Pune - 411033.

V-Ensure Pharma Technologies Pvt. Ltd. R&D Center, Navi Mumbai - 401 006. Tel: +91 22 27439001 / 8007 City No. 0296949201-0296949202  
 Indira College of Pharmacy, Tathawade, Pune - 411033. Tel: +91 20 27439001  
 www.v-ensure.com | info@v-ensure.com

---

**SCES'S Indira College of Pharmacy, Pune**

### Internship





Internship

Criterion - III – Research, Innovations & Extension      SSR      2022

**V-ENSURE**  
V-Ensure Pharma Technologies Pvt. Ltd.

TO WHOM SO EVER IT MAY CONCERN


This letter is to certify that Ms. Vaishnavi K. Kamthe, a 2<sup>nd</sup> Year M.Pharm student of SCES's Indira College of Pharmacy Pune, has successfully completed 6 months project training program with V-Ensure Pharma Technologies Private Limited. Her training tenure at R&D Center, Navi Mumbai was from 06<sup>th</sup> November 2021 to 30<sup>th</sup> April 2022.


She received training under the Guidance of Mr. Narayan Rajgode – Head of Analytical Research & Development department.


During the span, we found her enthusiastic and eager to learn. She was actively and diligently involved in the task assigned to her. Feedback and evaluation proved that she learned keenly. Moreover, her interpersonal and communication skills are good, which was evident from her project report.

We wish her a bright future.


For V-Ensure Pharma Technologies Pvt. Ltd.

  
Sandeep Arya  
HR Head





Indira College of Pharmacy  
Tathavade, Pune - 411033.




---

Regd. & Corp. Off: A-08 TTC Industrial Area, MIDC Phase, Navi Mumbai - 401106. Tel: +91 99 27600003 / 6667 CIN No.: U74900MH2010PTC001060  
Mfg. Unit: Plot No. 1432, Additional Parolgaon Industrial Area, Village C to Karadi Dohak, Taluka: Pimpri, Dist.: Pimpri Chinchwad, Pune - 411016. Tel. No. 7030027204  
www.v-ensure.com | info@v-ensure.com

**SCES'S Indira College of Pharmacy, Pune**

**Internship**

Criterion - III – Research, Innovations & Extension      SSR      2022      

**V-ensure**  
V-Ensure Pharma Technologies Pvt. Ltd.

TO WHOM SO EVER IT MAY CONCERN


This letter is to certify that Ms. Manisha S Bade, a 2<sup>nd</sup> Year M.Pharm student of SCES's Indira College of Pharmacy Pune, has successfully completed 6 months project training program with V-Ensure Pharma Technologies Private Limited. Her training tenure at R&D Center, Navi Mumbai was from 08<sup>th</sup> November 2021 to 30<sup>th</sup> April 2022.


She received training under the Guidance of Mr. Narayan Bokuale – Head of Analytical Research & Development department.


During the span, we found her enthusiastic and eager to learn. She was actively and diligently involved in the task assigned to her. Feedback and evaluations proved that she learned keenly. Moreover, her interpersonal and communication skills are good, which was evident from her project report.


We wish her a bright future.

For V-Ensure Pharma Technologies Pvt. Ltd.

  
Pralimp Arya  
HR Head



  
PRINCIPAL  
Indira College of Pharmacy  
Tathawade, Pune - 411033.




Regs. & Corp. Off: 4-63, TTC Industrial Area, MIDC Pharma, Navi Mumbai - 401 108. Tel: +91 22 27632053 / 007 CRN No: U74906MH 0010P TC202009  
Mfg. Unit: Plot No. 1432, Additional Patalganga Industrial Area, Village/Dist: Narode Surur, Taluka: Panvel, Dist: Raigad, Pin-410 206. Tel. No. 703227334

[www.v-ensure.com](http://www.v-ensure.com) | [info@v-ensure.com](mailto:info@v-ensure.com)

**SCES'S Indira College of Pharmacy, Pune**

### Internship

Criterion - III – Research, Innovations & Extension      SSR      2022



V-ENSURE  
V-Ensure Pharma Technologies Pvt. Ltd.

**TO WHOM SO EVER IT MAY CONCERN**


This letter is to certify that Mr. Sachin Dattatray Patil, a 2<sup>nd</sup> Year M.Pharm student of SCES's Indira College of Pharmacy Pune, has successfully completed 6 months project training program with V-Ensure Pharma Technologies Private Limited. His training tenure at R&D Center, Navi Mumbai was from 04<sup>th</sup> October 2021 to 31<sup>st</sup> March 2022.


He received training under the Guidance of Mr. Narayan Raitade – Head of Analytical Research & Development department.


During the span, we found his enthusiastic and eager to learn. He was actively and diligently involved in the task assigned to him. Feedback and evaluation proved that he learned keenly. Moreover, his Interpersonal and communication skills are good, which was evident from his project report.


We wish him a bright future.

For V-Ensure Pharma Technologies Pvt. Ltd.

  
Pradheep Arya  
HR Head




  
PRINCIPAL  
Indira College of Pharmacy  
Tathawade, Pune - 411033.



Regd. & Corp. Off: A-63, TTC Industrial Area, MIDC Khairni, Navi Mumbai - 400 705, Tel: +91 22 27630000 / 2007 CIN No: U74999MH-001019200003  
Mfg. Unit: Plot No. N-32, Additional Patilganga Industrial Area, Village/City: Kharde Budhvi, Taluka - Parner, Dist./ Raigad, Pin - 410 206, Tel. No. 2200221234  
[www.v-ensure.com](http://www.v-ensure.com) | [info@v-ensure.com](mailto:info@v-ensure.com)


SCES'S Indira College of Pharmacy, Pune

### Internship



[Back to Index](#)

### Offer Letter





Offer Letter

Criterion - III – Research, Innovations & Extension      SSR      2022

**V-ENSURE**  
V-Ensure Pharma Technologies Pvt. Ltd.

09<sup>th</sup> September' 2022

Ref : VE/IR/787

**Ms. Sheetal Mahadkar**  
P.M.G.P Colony, Rtn No 08,  
Bldg No B/27, Mankhurd,  
Mumbai 400 043

Contact No: (+91 ) 7715019040

**Dear Sheetal,**

This has reference to your application and the subsequent interview that you had with us. We are pleased to inform you that you have been selected to join our organization as **Jr. Research Associate - Formulation Research & Development** at our A63, MIDC Khairni, TTC Industrial Area, Navi Mumbai, Maharashtra, on or before **12<sup>th</sup> September' 2022** as per the mutually agreed terms.

A formal Appointment Letter will be issued to you after your joining our organization and completing necessary formalities etc.

Please bring with you the following documents while reporting for joining of duties, photocopies of your certificates and testimonials in support of your qualifications and date of birth along with four passport size colour photographs of yourself.

Please sign and return the duplicate of this letter as token of your acceptance.

We welcome you and wish you long and a prosperous career with us.

Yours Faithfully,

For V-ENSURE PHARMA TECH. PVT.LTD.

  
**Pradeep Arya**  
Head - HR & Admin



  
**PRINCIPAL**  
Indira College of Pharmacy  
Tathawade, Pune - 411033.


Regd. & Corp. Off: A-63, TTC Industrial Area MIDC Khairni, Navi Mumbai - 400 750. Tel: +91 022 7700703 / 0311 CR No: 174600046004200004  
Reg. Off: Plot No. W-20, Ashokrao Pathangale Institute Area, Shreeganesh, Khandesh Nagar, Solapur. Contact No: 416 001. Tel: No. 7122517014  
www.v-ensure.com | info@v-ensure.com

[Back to Index](#)



**MOU**

**Pharmaelite**



## MEMORANDUM OF UNDERSTANDING (MOU)

This Memorandum of Understanding (hereinafter called as the 'MOU') is entered into on this 1<sup>st</sup> day of July 2021

BETWEEN

**PHARMAELITE**, a academy with its registered address at 3/Kishor Kunj, 2<sup>nd</sup> Floor, N.S. Mankikar Marg, Sion, Mumbai-400022 (Operating from Mumbai, Maharashtra) the First Party represented herein by its authorized signatory, CEO & Founder – Mr. Dharmesh Mehta (hereinafter referred as 'PHARMAELITE', the institution which expression, unless excluded by or repugnant to the subject or context shall include its successors – in-office, representatives, employees, administrators & assigns).

AND

SCES's Indira College of Pharmacy and represented herein by its authorized signatory and representative Dr. Anagha Joshi (hereinafter referred to as "Institution", company which expression, unless excluded by or repugnant to the subject or context shall include its successors – in – office, employees, representatives, administrators and assigns.)

(PHARMAELITE & INSTITUTION are hereinafter jointly referred to as – "PARTIES")

WHEREAS:

1. PHARMAELITE ACADEMY is KNOWLEDGE PARTNER: an expert in training & consulting – education services
2. Both parties, PHARMAELITE & INSTITUTION, believe that collaboration and co-operation between themselves will promote more effective use of each of their resources and provide each of them with enhanced opportunities.
3. Parties intent to co-operate and focus their efforts on co-operation within area of up-skilling via WEBINARS, SEMINARS, CERTIFICATE COURSES, Strategic consultation, Education and training programs.
4. Both Parties, being legal entities in themselves desire to sign this MOU for advancing their mutual interest;
5. The INSTITUTION is engaged in Education, Skill development, R&D services in the fields of Higher & Technical Education, Management & Professional Courses, Employability, Entrepreneurship Development and related fields

NOW THEREFORE, IN CONSIDERATION OF THE MUTUAL PROMISES SET FORTH IN THIS MOU, THE PARTIES HERETO AGREE AS FOLLOWS:



**CLAUSE 1: CO-OPERATION**

- 1) Both Parties are united by common interests and objectives to empower youth/ students and they shall establish channels of communication and co-operation that will promote and advance their perspective operations within the Institutions and its related wings. The Parties shall keep each other informed of potential opportunities and shall share all non-confidential information that may be relevant to secure additional opportunities for one another. In case of exchange of confidential information being shared, the recipients(s) of such confidential information shall keep it protected like a reasonable and prudent man would for his own confidential information. Subject to a case-to-case basis prior written approval, INSTITUTION would arrange the logistics and pertinent operational expenses incurred for events/ interventions organized by INSTITUTION. It is recommended that INSTITUTION should use own infrastructure to reduce the operational expenses for any event (in-house) being hosted by INSTITUTION.
- 2) PHARMAELITE & INSTITUTION's co-operation will facilitate effective utilization of the subject matter expertise of PHARMAELITE & intellectual capabilities of students at INSTITUTION, providing significant inputs in developing suitable eco-systems, keeping in account needs of the INDUSTRY, to the INSTITUTION.
- 3) The general terms of co-operation shall be governed by this MOU. Both parties shall co-operate with each other and shall, as promptly as is reasonably and financially practical, and in order to encapsulate a case-to-case basis understanding of such financially practical cooperation enter into all relevant agreements, deeds and documents (the 'Definitive Documents') as may be required to give effect to the actions contemplated in terms of this MOU. The term of Definitive Documents shall be mutually decided between the parties. Along with the definitive documents, this MOU shall represent the entire understanding as to the subject matter hereof and shall supersede any prior understanding between the Parties on the subject matter hereof.

**CLAUSE 2: SCOPE OF THE MOU**

1. The budding graduates from INSTITUTION could play a key role in technological up-gradation, innovation and competitiveness of the industry. Both parties believe that close co-operation between the two would be of major benefit to the student community to enhance their skills and knowledge
2. PHARMAELITE will support in conducting various WEBINARS to train the students of INSTITUTION on skill-set according to Industry requirements including technical, professional and ethical skills to make them industry-ready
3. Internships and Placement support for students : PHARMAELITE will support in for INTERNSHIP & PLACEMENTS of STUDENTS of the INSTITUTION PARTY, if required
4. Faculty development programs : PHARMAELITE to train the faculties of the INSTITUTION for imparting industrial exposure/ training as per the Industrial requirement considering the National occupational standards in concerned sector, if available



5. Resource speaker/ person for Guest Lectures : PHARMAELITE to support in for GUEST LECTURES on various aspects like increasing technology, artificial intelligence, softwares, soft-skills,etc.
6. Research & development : Both parties may carry out the joint research activities in the field pertaining to the scope mentioned above.
7. Curriculum design: PHARMAELITE to support in for curriculum/ course design to guide in to help bridge the Industry-Academia GAP !!
8. Industrial training: Industry & institution interaction will give knowledge about latest updates/ developments in the PHARMACEUTICAL INDUSTRY. The Industrial sessions will help to prepare them for the increasing trends and further opportunities which industry holds in the future.
9. Parties to obtain internal approvals, consents, permissions and licenses of whatsoever nature required for offering the programs on terms specified herein
10. Expenses and commercials, if any, will be subjective to the nature and scope of engagement will be dealt separately

Both parties will decide on the nature of the intervention and commence once they mutually agree to it in writing prior to such intervention. In case of commercial activities, if any, BOTH PARTIES will have mutual consent on the commercial nature of the specific intervention and agree in writing (email, letter, notice, or any of other digital medium) before commencing any commercial/non-commercial engagement pertaining to the scope of the MOU.

#### CLAUSE 3: INTELLECTUAL PROPERTY

1. Nothing contained in this MOU shall, by express grant, implication, estoppel or otherwise, create in either party any right, title, interest or license in or to the intellectual property (including but not limited to know-how, inventions, patents, copyright and designs) of the other party
2. Both parties will respect each other privacy and IPR policies without any violation. In case of any violation of IPR, the MOU will be terminated immediately.

#### CLAUSE 4: VALIDITY

1. This agreement will be valid until it is expressly terminated by either Party on mutually agreed terms during August 2021 to August 2024 for a period of 3 years, PHARMAELITE and INSTITUTION, as the case may be, will take effective steps for implementation of this MOU. Any act on the part of KNOWLEDGE PARTNER, PHARMAELITE after termination of this agreement by the way of communication, correspondence, etc. shall not be construed as an extension of this MOU.
2. Both parties may terminate this MOU upon 30 calendar days notice in writing. In the event of termination, both parties have to discharge their obligations.

#### CLAUSE 5: RELATIONSHIP BETWEEN THE PARTIES



- Any divergence or difference derived from the interpretation or application of the MOU shall be resolved by arbitration between the parties as per the Arbitration Act, 1996. The place of the arbitration shall be at HEAD OFFICE of Indira College of Pharmacy.  
This undertaking is to be constructed in accordance with Indian Law with exclusive jurisdiction in the courts of Mumbai.
- It is expressly agreed that PHARMAELITE and INSTITUTION are acting under this MOU as Independent contractors, and the relationship established under this MOU shall not be construed as a partnership. Neither party is authorized to use the other Party's name in any way to make any representations or create any obligation or liability, expressed or implied, on behalf of the other party, without the prior written consent of the other party. Neither party shall leave, nor represent itself as having, any authority under terms of this MOU to make agreements of any kind in the name of or binding upon the other party to pledge the other party's credit, or to extend credit on behalf of other party.

AGREED BY:

For First Party:



Mr. Dharmesh Mehta, CEO

Authorized Signatory (Name and Sign)

For Second Party:



Authorized Signatory (Name and Sign)

PHARMAELITE	SCES's Indira College of Pharmacy
Maharashtra (IND)	Maharashtra
+91-9082087537/ +91-8433830815	+91- 9326003747
pharmaelite17@gmail.com hr@pharmaelite17.com dharmeshniprhyd@gmail.com	anagha.joshi@indiraicp.edu.in adminicp@indiraicp.edu.in
www.pharmaelite17.com	www.Indiraicp.edu.in

Seal/ Stamp:

First Party:



Second Party:



## SUMMARY



Shree Chanakya Education Society's  
**Indira College of Pharmacy, Pune**

"Redefining Pharmacy Education"

**NAAC : B++**

Approved by PCI, AICTE, New Delhi, Affiliated to SPPU & MSBTE, Recognized by Govt. of Maharashtra

### SUMMARY

Title: Activities carried out under MOU (Pharmaelite)			
S.No.	Name of the Activity	Topic	Class
1	Guest Lecture	Strategy for GPAT and NIPER preparation	B.Pharm, D. Pharm, Pharm D, M. Pharm
2	Guest Lecture	Transition from Academia to Industry with Pharmaelite <a href="https://youtu.be/dWZnNGPVa8U">https://youtu.be/dWZnNGPVa8U</a>	B.Pharm, D. Pharm, M. Pharm
3	Offline sessions on every Sunday	Novel innovative ways for GPAT/NIPER preparation	B.Pharm

*Mych*

Dr. Anagha M Joshi

PRINCIPAL  
 (Principal)  
 Indira College of Pharmacy  
 Tathawade, Pune - 411 033








Guest Lecture



*Shree Chanakya Education Society's*  
**INDIRA COLLEGE OF PHARMACY, PUNE**  
*"Redefining Pharmacy Education"*



*Mxh*  
INDIRA  
College of Pharmacy  
Pune - 411033.





Guest Lecture

Criterion - III

SSR

2022



Guest Lecture

SHREE CHANAKYA EDUCATION SOCIETY'S  
**INDIRA COLLEGE OF PHARMACY**

Approved by All India Council for Technical Education, and Pharmacy Council of India, New Delhi,  
Recognized by Govt. of Maharashtra, Directorate of Technical Education (MS)  
Affiliated to Savitribai Phule Pune University & Accredited by NAAC - B++  
ID No. PU/PN/Pharmacy/258/2006



Date: 10/07/2020

To,  
Mr. Dharmesh Mehata,  
Pharma Elite.

Sub: Session on "Strategy for GPAT and NIPER preparation."

Dear Sir,

We would like to express our sincere thanks to you. It was a unique opportunity for all the students to have an interaction with you. We are extremely thankful to you for sparing your valuable time and delivering such an excellent session to the B. Pharm students on "Strategy for GPAT and NIPER preparation".

We positively look forward for a long term association with you and for your valuable guidance in mentoring our students.

Thanking you,

Yours faithfully,



*(Signature)*  
(Dr. Anagha Joshi)  
Principal  
Indira College of Pharmacy  
Tathavade, Pune - 411 033

*(Signature)*  
PRINCIPAL

Indira College of Pharmacy  
Tathavade, Pune - 411 033

Niramay, 89/2 - A, New Pune - Mumbai Highway, Tathavade, Pune - 411 033, India.  
Tel. : +91-20 - 22933279, 66759603 /06 Fax : +91-20-66759601 E-mail : adminicp@indiralcp.edu.in Website: www.indiralcp.edu.in




SCES'S Indira College of Pharmacy, Pune



Guest Lecture



*Shree Chanakya Education Society's*  
**INDIRA COLLEGE OF PHARMACY, PUNE**  
*"Redefining Pharmacy Education"*



INDIRA A2I PHARMAELITE  
Academia to Industry, Bridge the Gap Course  
Powered by  
A2I and PHARMAELITE in association with SCES's Indira College of Pharmacy, Pune  
Organizes a session on  
**TRANSITION FROM  
ACADEMIA TO INDUSTRY  
WITH INDUSPHARMAELITE**  
23rd October 2021 11:00 AM  
Contact : +91-8433830815/8692820106 pharmaelite17@gmail.com | www.pharmaelite17.com

**Transition from Academia to Industry :-  
PHARMAELITE**



*nyeh*  
PRINCIPAL  
Indira College of Pharmacy  
Tathawade, Pune - 411033.



Guest Lecture



Shree Chanakya Education Society's  
**INDIRA COLLEGE OF PHARMACY, PUNE**  
*"Redefining Pharmacy Education"*



*myed*

**PRINCIPAL**  
Indira College of Pharmacy  
Tathawade, Pune - 411 032




Guest Lecture

Criterion - III

SSR

2022

Guest Lecture



**Shree Chanakya Education Society's**  
**INDIRA COLLEGE OF PHARMACY, PUNE**  
(Approved by Pharmacy Council of India, All India Council for Technical Education, New Delhi, Directorate of Technical Education (MS) and Government of Maharashtra- Affiliated to Savitribai Phule Pune University, Accredited by NAAC B++ Grade)  
ID No. PU/PN/Pharmacy/258/2006      AISHE Code- C-41396

---

Ref No. SCES/ ICP/ 2021-2022/      Date: 23<sup>rd</sup> October, 2021

To,  
Mr. Dharmesh Mehata,  
Pharmacist


Sub: Sessions on Transition from Academia to Industry with Induspharmelite™.


Dear Sir,

We would like to express our sincere thanks to you. It was a unique opportunity for all the students to have an interaction with you. We are extremely thankful to you for sparing your valuable time and delivering such an excellent session to our students on "Transition from Academia to Industry with Induspharmelite™".

We positively look forward for a long term association with you and for your valuable guidance in mentoring our students.

Thanking you,

Yours faithfully,  
  
(Dr. Anagha Joshi)  
Principal

  
PRINCIPAL  
Indira College of Pharmacy  
Tathawade, Pune - 411 033

Address : Niramay, B9/2 A, New Pune Mumbai Highway, Tathawade, Pune - 411033  
Tel No. 020- 66759601/ 603/604      Fax: 020-66759601  
Email- adminicp@indiracp.edu.in Website : www.indiracp.edu.in



SCES'S Indira College of Pharmacy, Pune

Guest Lecture


Criterion - III – Research, Innovations & Extension

SSR

2022



Guest Lecture



**INDIRA**

**PHARMAELITE**  
IN COLLABORATION WITH  
SCES'S INDIRA COLLEGE OF PHARMACY  
PUNE

have organized a OFFLINE session on

**"Novel Innovative Ways for GPAT/NIPER Preparation"**

**25th Sept,22 (Sunday)**  
**11:30am**

Venue :- Indira College of Pharmacy  
Niramay, New, Old Mumbai Rd, Tathawade  
Pune, Maharashtra 411033

8433830815    www.pharmaelite17.com    pharmaelite17@gmail.com



*myeh*  
**PRINCIPAL**  
Indira College of Pharmacy  
Tathawade, Pune - 411 033

SCES'S Indira College of Pharmacy, Pune

Guest Lecture


Criterion - III – Research, Innovations & Extension

SSR

2022



Thanks Letter





**PHARMAELITE**  
BRIDGING THE EDUCATIONAL GAP

pharmaelite17@gmail.com

8692820106 / 8433830815

Kishorkunj CHS room no.3  
N.S. Manikar Marg Sion Mumbai-400022

To,  
Dr.(Mrs.) Anagha Joshi,  
Principal,  
SCES's Indira College of Pharmacy, Pune

Date : 2<sup>nd</sup> Oct, 2022

**Subject :- GPAT and NIPER Entrance Exam MOU between PHARMAELITE and ICP**

Respected Madam,



This is to thank you and the management of SCES's Indira College of Pharmacy (ICP) for offering the college premises to jointly conduct offline coaching. The coaching for GPAT and NIPER preparation would involve online teaching on weekdays and 4 hours of offline teaching on every Sunday. One classroom with chalk and board facility would suffice for the offline classes.

Students of ICP as well as from nearby institutes will surely be benefitted due to this offline activity.

Considering the ongoing MOU between PHARMAELITE and ICP, PHARMAELITE would be delighted to offer 10% discount to ICP students on the course fees.


Once again, on behalf of PHARMAELITE team, I would like to express my heartfelt thanks to you for the kind cooperation.

Yours Sincerely,

Mr. Dharmesh Mehta.



  
**PRINCIPAL**  
**Indira College of Pharmacy**  
**Tathawade, Pune - 411 033**

*SCES'S Indira College of Pharmacy, Pune*

[Back to Index](#)

MOUManipal Institute of Virology

This MEMORANDUM OF UNDERSTANDING (hereinafter referred to as "AGREEMENT") is made and entered into as on the 15<sup>th</sup> day of March, 2022 and deemed to be effective from 1<sup>st</sup> day of APRIL, 2022 ("EFFECTIVE DATE") by and between:

**Manipal Academy of Higher Education (MAHE)**, a deemed to be University under Section 3 of UGC Act, 1956, having its registered office at Madhav Nagar, Manipal – 576104, Karnataka, India, on behalf of **Manipal Institute of Virology** (hereinafter referred to as "MIV"), a constituent unit of MAHE, and represented by its Registrar, Dr. Narayana Sabhahit, hereinafter referred to as the **FIRST PARTY**

AND

**SCES's Indira College of Pharmacy (ICP)**, established under the aegis of Savitribai Phule Pune University, having its office at Ganeshkhind Pune, Maharashtra 411007 and represented by its **Principal, Dr. Anagha Joshi** hereinafter referred to as the **SECOND PARTY**

**Whereas –**

- A. MIV, a constituent unit of the First Party, is a center for training, education and research in virology with the state-of-the-art laboratory. Antiviral testing services is a platform to support the research related activities of interested academic and industrial collaborators.
- B. Both parties wish to enter into an Agreement wherein the First Party, through its constituent unit MIV, shall provide testing facility on a nominally charged basis for the assessment of *in vitro* cytotoxicity and *in vitro* antiviral activity of the test samples provided by the Second Party. These charges are mainly towards the cost of consumables, required for the execution of the experiments involved.
- C. Both parties are higher education institutions with full legal capacity to establish commitments, and whose mission includes providing quality learning opportunities for its students and communities, as well as promoting academic research;
- D. Both parties having the facility and objective to undertake research activity, have the required infrastructure, personnel and research minded employees with right aptitude,
- E. Both the institutions have agreed to carry out research projects with special emphasis on antiviral drug discovery and development.

**Now, Therefore**, in consideration of mutual agreements, covenants, representations and warranties set forth in this Agreement, the Parties hereby agree to the following clauses,



- 1) The Commencement Date of this Agreement shall be 1<sup>st</sup> day of APRIL, 2022. This Agreement shall be valid for a period of 3 (three) years from the Commencement Date.
- 2) This agreement shall establish the criteria under which MAHE and ICP will carry out joint collaborative activities of mutual interests, particularly in the field of antiviral drug discovery and development to improve quality of research and build the capabilities of their students and faculty members.
- 3) Both the parties agree to share their expertise for academic and research collaborations of mutual interests.
- 4) The parties may, jointly or separately, endeavor to obtain financial resources from other institutions, government agencies and national and international organizations for the development of activities associated with the implementation of any Specific Agreement.
- 5) Both parties agree that any of the laws and rules laid down by MAHE, ICP, State Government, Central Government, UGC and appropriate regulatory authorities will be strictly adhered to and its change that may occur time to time in future are followed.
- 6) The parties shall perform the research studies in compliance with (i) the Agreement (ii) the drafted Protocols, (iii) approval of institutional review board / institutional ethics committee (IEC), and (iv) generally accepted laboratory and pharmacological practices as recommended in their latest guidelines of Institutional Bio-Safety committee (IBSC), Department of Biotechnology-India (DBT) and Indian Council of Medical research (ICMR, MoHFW, Govt. of India)
- 7) Both the parties share the rights to use the data and results generated from their collaborative study; for their internal research, educational (including teaching) purposes, publication and/or presentation in any reputed journal and/or conference, patents with receiving due acknowledgment from the other Party.
- 8) Both the parties agree to publish the results irrespective of whether it is positive or negative and that they include each other's name with prior consent from the other party.
- 9) The parties agree to maintain the confidentiality on information related to the cooperative activities such as financial, scientific, corporate, industrial, product and business information disclosed by the other Party and/or its Affiliates and any and all results, information, data and documents generated, produced or obtained.
- 10) The list of antiviral screening tests with respective codes and charges is enclosed (Please refer **Annexure A**). The rate list shall be valid for 1 (one) year from the date of commencement and 18% GST shall be charged EXTRA by MAHE as per the prevailing tax norms.
- 11) If the Second Party agrees to include the First Party as co-authors in any related scientific publications or share the rights of any intellectual property generating out of this work, a discounted rate as mentioned in Annexure A, may be applied to cover only the working costs involved.



- 12) The test samples shall be packed and dispatched by the Second Party and collected by the First Party. The First Party shall not be responsible for any damage or loss of the test samples caused due to oversight/negligence during dispatch or in transit. The responsibility to pack and dispatch the samples on time, shall lie with the Second Party.
- 13) The budget for the experimental expenditures will be prepared by the First Party depending on the number of test samples requested for antiviral testing by the Second Party.
- 14) Billing shall be done by the First Party and a statement/Invoice for payment, once ready will be sent to the Second Party. Payments shall be made within 10 days of receipt of the statement.
- 15) Depending upon the standard testing procedure and time required for performing the test, the First Party shall send the reports of the test samples by email to the Second Party.
- 16) The First Party shall not be responsible for any delays resulting from infrastructural break down or any other specific issues that prevent from undertaking the test which are out of control of the management of the First Party.
- 17) The First Party shall be conducting all the tests following standardized laboratory protocols and will be responsible for the authenticity of the test results. In case of any disagreements from the Second Party regarding outcome of the results obtained, the First Party should not be held responsible.
- 18) The present Agreement will become valid upon signature by both parties and shall remain in effect for a period of three years from its effective date. The agreement may be amended at any time by a written agreement signed by authorized representatives of both parties.
- 19) **Termination of the Agreement:** Termination of the Agreement may be effected by a notice, in writing, 1 (one) month prior, by either Party. If the Second Party wishes to terminate the Agreement, they shall inform the First Party in writing, about the intention to discontinue the Agreement and clear all outstanding amount. However, in any circumstances the paid amount shall not be refunded.
- 20) In case of continuance of the collaborative work, after completion of the term of the Agreement, a renewal for extension is mandatory.
- 21) This Agreement shall be governed by Indian Laws and in case of any disputes, it shall be resolved amicably by the Parties, primarily through mediation between the Chief Executives of the two organizations.





In Witness Whereof, each Party to this Agreement has caused it to be executed by its duly authorized representative as of the Commencement Date.

For and on behalf of

**Manipal Academy of Higher Education, Manipal**





Name: Dr. Narayana Sabhahit

Title: Registrar

For and on behalf of

**Indira College of Pharmacy, Pune**




Name: Dr. Anagha Joshi

Title: Principal

For and on behalf of

**Manipal Institute of Virology, Manipal**




Name: Dr. Chiranjay Mukhopadhyaya

Title: Director, MIV, MAHE

For and on behalf of

**Indira College of Pharmacy, Pune**



Name: Dr. Madhur Kulkarni

Title: Associate Professor  
& HOD- Pharmaceutics

**ANNEXURE A**  
**CYTOTOXICITY/ANTIVIRAL SCREENING PANEL**

RATE LIST FOR ACADEMIC COLLABORATORS			
CODE	CATEGORY & TEST	PRICE (INR)	DISCOUNTED PRICE (INR)
VIRS008	Cytotoxicity assessment per test sample per cell line	5000	3000
VIRS009	Antiviral screening against Herpes simplex virus 1- post-infection treatment with each test sample	10000	6000
VIRS010	Antiviral screening against Herpes simplex virus 1- pre-infection treatment with each test sample	10000	6000
VIRS011	Antiviral screening against Herpes simplex virus 1- simultaneous treatment with each test sample	10000	6000
VIRS012	Antiviral screening against Herpes simplex virus 2- post-infection treatment with each test sample	10000	6000
VIRS013	Antiviral screening against Herpes simplex virus 2- pre-infection treatment with each test sample	10000	6000
VIRS014	Antiviral screening against Herpes simplex virus 2- simultaneous treatment with each test sample	10000	6000
VIRS015	Antiviral screening against Influenza A(H1N1) pdm09 virus- post-infection treatment with each test sample	10000	6000
VIRS016	Antiviral screening against Influenza A(H1N1) pdm09 virus- pre-infection treatment with each test sample	10000	6000
VIRS017	Antiviral screening against Influenza A(H1N1) pdm09 virus- simultaneous treatment with each test sample	10000	6000



SUMMARY



*Shree Chanakya Education Society's*  
**Indira College of Pharmacy, Pune**  
*"Redefining Pharmacy Education"*

**NAAC: B++**

Approved by PCI, AICTE, New Delhi, Affiliated to SPPU & MSBTE, Recognized by Govt. of Maharashtra

SUMMARY

A project proposal has been submitted collaborately for the seed grant to Manipal Institute of Virology.



Dr. Anagha M Joshi  
**PRINCIPAL**  
Indira College of Pharmacy  
Tathawade, Pune - 411 033

**Collaborative Project**

*Shree Chanakya Education Society's*  
**Indira College of Pharmacy, Pune**  
*"Redefining Pharmacy Education"*

**NAAC: B++**

Approved by PCI, AICTE, New Delhi, Affiliated to SPPU &amp; MSBTE, Recognized by Govt. of Maharashtra

**Project Title:**

Screening of two drug formulations (Tenofovir disoproxil fumarate and Zinc acetate dihydrate) and their combination for pre-exposure prophylaxis and treatment of Herpes Simplex Virus-2 (HSV-2) infections

Principal Investigator:

Dr Piya Paul Mudgal, Associate Professor, Manipal Institute of Virology


Co-Principal Investigator:

Dr. Madhur Kulkarni, Associate Professor, Indira College of Pharmacy

Grant details:

Seed grant of INR 1 Lakh applied to Manipal Institute of Virology for interdisciplinary research of 1 year duration



  
**PRINCIPAL**  
Indira College of Pharmacy  
Tathawade, Pune - 411 033

[Back to index](#)